www 669

合集下载

NPort 6150 6250 Series Quick Installation Guide

NPort 6150 6250 Series Quick Installation Guide

P/N: 1802061500016 *1802061500016*NPort 6150/6250 Series Quick Installation GuideEdition 9.0, November 2016Technical Support Contact Information/supportMoxa Americas:Toll-free: 1-888-669-2872 Tel: 1-714-528-6777 Fax: 1-714-528-6778 Moxa China (Shanghai office): Toll-free: 800-820-5036 Tel: +86-21-5258-9955 Fax: +86-21-5258-5505 Moxa Europe:Tel: +49-89-3 70 03 99-0 Fax: +49-89-3 70 03 99-99 Moxa Asia-Pacific:Tel: +886-2-8919-1230 Fax: +886-2-8919-1231 Moxa India:Tel: +91-80-4172-9088 Fax: +91-80-4132-10452016 Moxa Inc. All rights reserved.OverviewThe NPort 6150/6250 series secure serial device servers provide reliable serial-to-Ethernet connectivity for a wide range of serial devices. The NPort 6150/6250 support TCP Server, TCP Client, UDP, andPair-Connection operation modes to ensure the compatibility of network software. In addition, the NPort 6150/6250 also support Secure TCP Server, Secure TCP Client, Secure Pair-Connection, and Secure Real COM modes for security critical applications such as banking, telecom, access control, and remote site management.Package ChecklistBefore installing a NPort 6150/6250 secure device server, verify that the package contains the following items:• 1 NPort 6150 or NPort 6250•Power adapter (does not apply to -T models)• 2 wallmount ears•Documentation and software CD•Quick installation guide (this guide)•Warranty cardOptional Accessories•DK-35A: DIN-rail mounting kit (35 mm)•DIN-rail power supply•CBL-RJ45M9-150: 8-pin RJ45 to male DB9 cable•CBL-RJ45M25-150: 8-pin RJ45 to male DB25 cableNOTE: Please notify your sales representative if any of the above items are missing or damaged.Hardware IntroductionNPort 6150NPort 6250Reset Button—Press the Reset Button continuously for 5 sec to load factory defaults. Use a pointed object, such as a straightened paper clip or toothpick, to press the reset button. This will cause the Ready LED to blink on and off. The factory defaults will be loaded once the Ready LED stops blinking (after about 5 seconds). At this point, you should release the reset button.LED IndicatorsAdjustable pull high/low resistor for RS-422/485 (150 K Ω or 1 K Ω)Jumpers are used to set the pull high/low resistors. The default is 150 kΩ. Short the jumpers to set this value to 1 kΩ. Do not use the 1 kΩ setting with RS -232 mode, since doing so will degrade the RS-232 signals and shorten the communication distance.Hardware Installation ProcedureSTEP 1: Connect the 12-48 VDC power adaptor to the NPort 6150 andthen plug the power adaptor into a DC outlet.STEP 2: For first-time configuration, use a cross-over Ethernet cable toconnect the NPort 6150 directly to your computer’s Ethernet cable. For connecting to a network, use a standardstraight-through Ethernet cable to connect to a hub or switch.STEP 3: Connect the NPort 6150’s serial port to a serial device.Placement OptionsThe NPort 6150/6250 can be placed flat on a desktop or other horizontal surface. In addition, you may use the DIN-rail or wallmount options, as illustrated below.WallmountDin RailSoftware Installation InformationThe Documentation and software CD contains the user’s manual, NPort Search Utility, and the PComm Lite Suite. Insert the CD into yourcomputer’s CD-ROM drive and follow the on-screen instructions. Please refer to the user’s manual for additional details on using the NPort Search Utility and PComm Lite.Pin Assignments and Cable WiringTwo serial cables for connecting the NPort 6150 to a serial device can be purchased separately. The wiring diagrams for the two cables are shown below.。

色彩数字双速大像素CV-M7摄像头说明书

色彩数字双速大像素CV-M7摄像头说明书

Color Digital Double Speed Megapixel CV-M7•2/3” progressive scan color CCD Camera•RGB primary mosaic filter (Bayer) for host based RGB decoding •1300 (h) x 1030 (v) 6.7 µm square pixels•8 bit video output (digitization via 10 bit A/D) as LVDS (EIA 644)•EIA 644 and Camera Link Versions available•Full 1030 lines frame readout in 1/24 second•Partial scan 1/2, 1/4, 1/8 for higher frame rate•S/N ratio >57 dB•Shutter 1/24 to 1/10,000 second in 10 steps•Edge pre-select and pulse width external trigger modes •Frame-delay readout•Unique smear reduction circuit•Pixel synchronized image transfer•Setup by RS 232C or switches•Windows 95/98/NT setup software Seri a l In t e r face Co n tr o l T o o lrs c232Progressive ScanThe leading manufacturer of high performance camera solutions<<<<<<<<>><<<<>>>><<<<>><<>><<<><><><><><<>><><><<>><><>Specifications for CV-M7SpecificationsCV-M7Visit our web site on JAI Corporation, Japan Phone +81 45 933 5400Fax +81 45 931 6142www.jai-corp.co.jpJAI A .S, DenmarkPhone +45 4457 8888Fax +45 4491 JAI UK Ltd., EnglandPhone +44 1442 879 669Fax +44 1442 879 JAI America Inc., USAPhone (Toll-Free) +1 877 472-5909Phone +1 949 472-5900Fax +1 949 JAI Vision OY, Finland Phone +358 9 8256220Fax +358 9 870 3345C o m p a n y a n d p r o d u c t n a m e s m e n t i o n e d i n t h i s d a t a s h e e t a r e t r a d e m a r k s o r r e g i s t e r e d t r a d e m a r k s o f t h e i r r e s p e c t i v e o w n e r s .J A I A .S c a n n o t b e h e l d r e s p o n s i b l e f o r a n y t e c h n i c a l o r t y p o g r a p h i c a l e r r o r s a n d r e s e r v e s t h e r i g h t t o m a k e c h a n g e s t o p r o d u c t s a n d d o c u m e n t a t i o n w i t h o u t p r i o r n o t i f i c a t i o n .Scanning system Progressive scan Pixel clock 40.49 MHzLine frequency 25.056 kHz. (1616 pixel clock/line)Frame rate 24 frames/sec. (1044 lines/frame)CCD sensor RGB color 2/3” IT CCD Sensing area 8.7 mm (h) x 6.9 mm (v)Picture elements 1300 (h) x 1030 (v) effective pixels Picture elements in video output Full:1280 (h) x 1024 (v). 24 fps 1/2 Partial:1280 (h) x 514 (v). 45 fps 1/4 Partial:1280 (h) x 250 (v). 79 fps 1/8 Partial:1280 (h) x 130 (v). 120 fpsCell size6.7 (h) x 6.7 (v) µm Center wavelength Blue 470 nm of spectral bands Green 540 nm Red 640 nmSensitivity on sensor 0.2 Lux (Max. gain, 50% video)S/N ratio>57 dB Video A/D conversion 10 bitVideo output options Digital 8 bit LVDS (EIA 644)Digital 10 bit Camera LinkGainManual Gain range 0 to + 12 dBGamma1.0Synchronization Int. X-tal.Trigger inputLVDS or TTL 2 – 5 V *Frame enable output LVDS */Camera Link Line enable output LVDS */Camera Link Pixel clock output LVDS */Camera LinkShutter 1/24, 1/50, 1/100, 1/200, 1/400, 1/800,1/1500, 1/3000, 1/5000, 1/10,000 sec.Partial scan Normal, 1/2, 1/4, 1/8Trigger modes Off, Edge pre-select, Pulse width controlReadout modes Normal, Smearless and Frame delayCamera setup Shutter, Trigger, Scanning,switches on rear Readout systemRS 232C control Shutter, Trigger, +/- slope, Scanning,Readout, Gain, Black levelOperating temperature -5°C to +45°CHumidity 20 – 80% non-condensingPower12V DC ± 10%. 5.5WLens mount C-mountDimensions 40 x 50 x 90 mm (HxWxD)Weight250 g* Polarity positive/negative by internal settingOrdering InformationCV-M7 Color Digital Double Speed Megapixel Progressive Scan CV-M7CL Color Digital Double Speed Megapixel Progressive ScanSpectral SensitivityConnection Description DimensionsDC-IN/TRIG.Pin1Ground 2+12V DC 3Ground 4Test 5Ground 6RXD input 7TXD output 8Ground 9FEN output 10TRIG in (TTL)11+12V DC 12GroundLVDS in-/outputsPin Signal 1, 14+/- Do Video out (LSB)2, 15+/- D1Video out 3, 16+/- D2Video out 4, 17+/- D3Video out 5, 18+/- D4Video out 6, 19+/- D5Video out 7, 20+/- D6Video out8, 21+/- D7Video out (MSB)9, 22+/- TRIGTrigger in 10, 23N.C.11, 24+/- LEN Line enable 12, 25+/- FEN Frame enable 13, 26+/- PCLK Pixel clockFront viewTrigger/Readout ModesSwitch Setting26 pin MDR connector 3M 10226-1A10JLDigital I/OLVDS in and outputs circuits NS.DS90C031/DS90C032For Camera Link pin configuration,see user manualSide viewBottom viewRear viewEXT. TRIGGERSHUTTER1/241/501/1001/2001/4001/8001/15001/30001/50001/10,000S e c o n d sNormal <> Smearless Local<> RS 232CF u l lO f f1/2 p a r t i a l p r e -SCANSMEAR-LESS CONTROLE d g e1/4 p a r t i a l P u l s e 1/8 p a r t i a l F r a m e OFFONEDGEPRE-SELECT PULSE WIDTHFRAME-DELAY READOUTTriggerTriggerTrigger Exposure shutter timeExposureExposure shutter time ReadoutReadoutReadout12345678910..depth1312614s e l e c t Wave Length (nm)R e l a t i v e r e s p o n s eHirose HR10A-10R-12P 31010732.05.01.3000d e l a yw i d t h。

UB01KW035D;UB01KW035C;UB04KW015F;UB04KW015C;UB04KW015D;中文规格书,Datasheet资料

UB01KW035D;UB01KW035C;UB04KW015F;UB04KW015C;UB04KW015D;中文规格书,Datasheet资料

UB Indicators M21A c c e s s o r i e s S u p p l e m e n t T a c t i l e sK e y l o c k s R o t a r i esP u s h b u t t o n s I l l u m i n a t e d P B S l i d e sP r o g r a m m a b l e T o g g l e sR o c k e r sT o u c h T i l t Complement to UB PushbuttonsDESCRIPTION FOR TYPICAL ORDERING EXAMPLEUB01KW035C-JCRed, Bright LEDTYPICAL INDICATOR ORDERING EXAMPLEClear Lens with Red Diffuser Square with PCB MountingSilver, Straight PC Terminals* Wire harness & cable assemblies offered only in Americas/UB IndicatorsM22A c c e s s o r i e sS u p p l e m e n tT a c t i l e sK e y l o c k sR o t a r i e sP u s h b u t t o n sI l l u m in a t e d P BSl i d e sP r o g r a m m a b le R o c k e r sT ou c hTi ltT o g g l e sComplement to UB PushbuttonsThe electrical specifications shown are determined at a basic temperature of 25°C. If the source voltage exceeds the rated voltage, a ballast resistor is required. The resistor value can be calculated by using the formula in the Supplement section.The LED is an integral part of the indicator and not available separately.Full Face Illuminated Cap for Bright LEDLens/DiffuserColors Available for Square Cap:Lens/DiffuserColors Available for Rectangular Cap:AT4074 LensAT4117LensAT4075 DiffuserAT4118 DiffuserLens & Diffuser Material: Polycarbonate Lens Finish: Glossy Diffuser Finish: TexturedFull Face Illuminated Cap for Super Bright LEDColor Codes:A BlackB WhiteC RedD Amber F Green J ClearJBLens/DiffuserColors Available for Square Cap:AT4074 Lens & AT4075 Diffuser (Dimensioned above)Rectangular lens & diffuser are not available for combining with super bright LED.Lens & Diffuser Material: Polycarbonate Lens Finish: Glossy Diffuser Finish: TexturedLED COLORS & SPECIFICATIONSCAP TYPES & COLOR COMBINATIONSABBlack Cap with Translucent White Window for LED DisplayAT4120 Rectangular for Bright LEDMaterial: PolycarbonateFinish: MatteAT4119 Square for Bright and Super Bright LEDSpot Illuminated CapsCBCC CJDB DDDJ FB FF FJ JBJC JD JF JJCB CC DB DDFB FF JB JCJDJF/UB IndicatorsM23A c c e s s o r i e sS u p p l e m e n tT ac t i l e sK e y lo c k sR o t a r ie s P us h b u t t o n sIl l u m i n at edP B S l i d esP r o g r a m m a bl e T o g g l e sR o c k e r s T o u c hT i l tComplement to UB PushbuttonsSquare • PCB MountSquare • Snap-in Mount • Built-in BezelRectangular • PCB MountRectangular • Snap-in Mount • Built-in BezelRectangular • Snap-in Mount • Built-in Side BarriersUB01KW035C-JCUB03KW035F-FFUB04KW015C-JCUB06KW015D-DDUB06BKW015F-FFTYPICAL INDICATOR DIMENSIONSPanel Thickness:1.0 ~ 3.2mm (.039 ~ .126”)Panel Thickness:1.0 ~ 3.2mm (.039 ~ .126”)Panel Thickness:1.0 ~ 3.2mm (.039 ~ .126”)/分销商库存信息:NKK-SWITCHUB01KW035D UB01KW035C UB04KW015FUB04KW015C UB04KW015D UB01KW035D-DD UB04KW015C-JC UB04KW015D-DD UB04KW015F-FF UB04KW015C-CC UB04KW015C-JB UB06KW015CUB06KW015D UB06KW015F UB03KW035F-JB UB06KW015C-CB UB06KW015D-JB UB06KW015F-FF UB06KW015F-FB UB06KW015C-CC UB06KW015D-DD UB01KW036G-JB UB01KW036G UB04KW016B-JB UB04KW016F-JB UB06KW016B-CC UB06KW016B-DD UB06KW016B-FF UB06KW016B-JB UB06KW016BUB04KW016G-JB UB01KW035C-CC。

entresto-LCZ696(sacubitril and valsartan)-说明书

entresto-LCZ696(sacubitril and valsartan)-说明书

HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO.ENTRESTO™ (sacubitril and valsartan) tablets, for oral useInitial U.S. Approval: 2015WARNING: FETAL TOXICITYSee full prescribing information for complete boxed warning.∙When pregnancy is detected, discontinue ENTRESTO as soon as possible. (5.1)∙Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)----------------------------INDICATIONS AND USAGE--------------------------- ENTRESTO is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. (1.1) ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB. (1.1)-----------------------DOSAGE AND ADMINISTRATION----------------------- ∙The recommended starting dose of ENTRESTO is 49/51 mg (sacubitril/valsartan) twice-daily. Double the dose of ENTRESTO after 2 to4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan)twice-daily, as tolerated by the patient. (2.1)∙Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for: -patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously takinga low dose of these agents (2.2)-patients with severe renal impairment (2.3)-patients with moderate hepatic impairment (2.4)Double the dose of ENTRESTO every 2 to 4 weeks to the targetmaintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, astolerated by the patient. (2.2, 2.3, 2.4) ----------------------DOSAGE FORMS AND STRENGTHS--------------------- ∙Film-coated tablets (sacubitril/valsartan): 24/26 mg; 49/51 mg; 97/103 mg(3)--------------------------------CONTRAINDICATIONS----------------------------- ∙Hypersensitivity to any component. (4)∙History of angioedema related to previous ACE inhibitor or ARB therapy.(4)∙Concomitant use with ACE inhibitors. (4, 7.1)∙Concomitant use with aliskiren in patients with diabetes. (4, 7.1)------------------------WARNINGS AND PRECAUTIONS----------------------- ∙Observe for signs and symptoms of angioedema and hypotension. (5.2, 5.3) ∙Monitor renal function and potassium in susceptible patients. (5.4, 5.5)-------------------------------ADVERSE REACTIONS------------------------------ Adverse reactions occurring ≥5% are hypotension, hyperkalemia, cough, dizziness, and renal failure. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or /medwatch.-------------------------------DRUG INTERACTIONS------------------------------ ∙Dual blockade of the renin-angiotensin system: Do not use with an ACEi, do not use with aliskiren in patients with diabetes, and avoid use with an ARB. (4, 7.1)∙Potassium-sparing diuretics: May lead to increased serum potassium. (7.2) ∙NSAIDs: May lead to increased risk of renal impairment. (7.3)∙Lithium: Increased risk of lithium toxicity. (7.4)------------------------USE IN SPECIFIC POPULATIONS----------------------- ∙Lactation: Breastfeeding or drug should be discontinued. (8.2)∙Severe Hepatic Impairment: Use not recommended. (2.4, 8.6)See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 7/2015_______________________________________________________________________________________________________________________________________FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: FETAL TOXICITY1 INDICATIONS AND USAGE1.1 Heart Failure2 DOSAGE AND ADMINISTRATION2.1 Dosing2.2 Dose Adjustment for Patients Not Taking an ACE inhibitor orARB or Previously Taking Low Doses of These Agents2.3 Dose Adjustment for Severe Renal Impairment2.4 Dose Adjustment for Hepatic Impairment3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND PRECAUTIONS5.1 Fetal Toxicity5.2 Angioedema5.3 Hypotension5.4 Impaired Renal Function5.5 Hyperkalemia6 ADVERSE REACTIONS6.1 Clinical Trials Experience7 DRUG INTERACTIONS7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System7.2 Potassium-Sparing Diuretics7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) IncludingSelective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)7.4 Lithium8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.4 Pediatric Use8.5 Geriatric Use8.6 Hepatic Impairment8.7 Renal Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2 Animal Toxicology and/or Pharmacology14 CLINICAL STUDIES16 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed._______________________________________________________________________________________________________________________________________FULL PRESCRIBING INFORMATIONWARNING: FETAL TOXICITY• When pregnancy is detected, discontinue ENTRESTO as soon as possible (5.1)• Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1)USAGE1 INDICATIONSANDFailure1.1 HeartENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.2 DOSAGE AND ADMINISTRATION2.1 DosingENTRESTO is contraindicated with concomitant use of an angiotensin-converting enzyme (ACE) inhibitor. If switching from an ACE inhibitor to ENTRESTO allow a washout period of 36 hours between administration of the two drugs [see Contraindications (4) and Drug Interactions (7.1)].The recommended starting dose of ENTRESTO is 49/51 mg twice-daily.Double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.2.2 Dose Adjustment for Patients Not Taking an ACE inhibitor or ARB or Previously Taking Low Doses ofThese AgentsA starting dose of 24/26 mg twice-daily is recommended for patients not currently taking an ACE inhibitor or an angiotensin II receptor blocker (ARB) and for patients previously taking low doses of these agents. Double the dose of ENTRESTO every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.2.3 Dose Adjustment for Severe Renal ImpairmentA starting dose of 24/26 mg twice-daily is recommended for patients with severe renal impairment (eGFR <30mL/min/1.73 m2). Double the dose of ENTRESTO every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.No starting dose adjustment is needed for mild or moderate renal impairment.2.4 Dose Adjustment for Hepatic ImpairmentA starting dose of 24/26 mg twice-daily is recommended for patients with moderate hepatic impairment (Child-PughB classification). Double the dose of ENTRESTO every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.No starting dose adjustment is needed for mild hepatic impairment.Use in patients with severe hepatic impairment is not recommended.3 DOSAGE FORMS AND STRENGTHSENTRESTO is supplied as unscored, ovaloid, film-coated tablets in the following strengths:ENTRESTO 24/26 mg, (sacubitril 24 mg and valsartan 26 mg) are violet white and debossed with “NVR” on one side and “LZ” on the other side.ENTRESTO 49/51 mg, (sacubitril 49 mg and valsartan 51 mg) are pale yellow and debossed with “NVR” on one side and “L1” on the other side.ENTRESTO 97/103 mg, (sacubitril 97 mg and valsartan 103 mg) are light pink and debossed with “NVR” on one side and “L11” on the other side.4 CONTRAINDICATIONSENTRESTO is contraindicated:∙in patients with hypersensitivity to any component∙in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2)]∙with concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor [see Drug Interactions (7.1)]∙with concomitant use of aliskiren in patients with diabetes [see Drug Interactions (7.1)].5 WARNINGS AND PRECAUTIONSToxicity5.1 FetalENTRESTO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO. However, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus [see Use in Specific Populations (8.1)].5.2 AngioedemaENTRESTO may cause angioedema. In the double-blind period of PARADIGM-HF, 0.5% of patients treated with ENTRESTO and 0.2% of patients treated with enalapril had angioedema [see Adverse Reactions (6.1)]. If angioedema occurs, discontinue ENTRESTO immediately, provide appropriate therapy, and monitor for airway compromise. ENTRESTO must not be re-administered. In cases of confirmed angioedema where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, administer appropriate therapy, e.g., subcutaneous epinephrine/adrenaline solution1:1000 (0.3 mL to 0.5 mL) and take measures necessary to ensure maintenance of a patent airway.ENTRESTO has been associated with a higher rate of angioedema in Black than in non-Black patients.Patients with a prior history of angioedema may be at increased risk of angioedema with ENTRESTO [see Adverse Reactions (6.1)]. ENTRESTO should not be used in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy [see Contraindications (4)].5.3 HypotensionENTRESTO lowers blood pressure and may cause symptomatic hypotension. Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. In the double-blind period of PARADIGM-HF, 18% of patients treated with ENTRESTO and 12% of patients treated with enalapril reported hypotension as an adverse event [see Adverse Reactions (6.1)], with hypotension reported as a serious adverse event in approximately 1.5% of patients in both treatment arms. Correct volume or salt depletion prior to administration of ENTRESTO or start at a lower dose.If hypotension occurs, consider dose adjustment of diuretics, concomitant antihypertensive drugs, and treatment of other causes of hypotension (e.g., hypovolemia). If hypotension persists despite such measures, reduce the dosage or temporarily discontinue ENTRESTO. Permanent discontinuation of therapy is usually not required.5.4 Impaired Renal FunctionAs a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), decreases in renal function may be anticipated in susceptible individuals treated with ENTRESTO. In the double-blind period of PARADIGM-HF, 5% of patients in both the ENTRESTO and enalapril groups reported renal failure as an adverse event [see Adverse Reactions (6.1)]. In patients whose renal function depends upon the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists hasbeen associated with oliguria, progressive azotemia and, rarely, acute renal failure and death. Closely monitor serum creatinine, and down-titrate or interrupt ENTRESTO in patients who develop a clinically significant decrease in renal function [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].As with all drugs that affect the RAAS, ENTRESTO may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis. In patients with renal artery stenosis, monitor renal function.5.5 HyperkalemiaThrough its actions on the RAAS, hyperkalemia may occur with ENTRESTO. In the double-blind period of PARADIGM-HF, 12% of patients treated with ENTRESTO and 14% of patients treated with enalapril reported hyperkalemia as an adverse event [see Adverse Reactions (6.1)]. Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of ENTRESTO may be required [see Dosage and Administration (2.1)].6 ADVERSEREACTIONSClinically significant adverse reactions that appear in other sections of the labeling include:∙Angioedema [see Warnings and Precautions (5.2)]∙Hypotension [see Warnings and Precautions (5.3)]∙Impaired Renal Function [see Warnings and Precautions (5.4)]∙Hyperkalemia [see Warnings and Precautions (5.5)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In the PARADIGM-HF trial, subjects were required to complete sequential enalapril and ENTRESTO run-in periods of (median) 15 and 29 days, respectively, prior to entering the randomized double-blind period comparing ENTRESTO and enalapril. During the enalapril run-in period, 1,102 patients (10.5%) were permanently discontinued from the study, 5.6% because of an adverse event, most commonly renal dysfunction (1.7%), hyperkalemia (1.7%) and hypotension (1.4%). During the ENTRESTO run-in period, an additional 10.4% of patients permanently discontinued treatment, 5.9% because of an adverse event, most commonly renal dysfunction (1.8%), hypotension (1.7%) and hyperkalemia (1.3%). Because of this run-in design, the adverse reaction rates described below are lower than expected in practice.In the double-blind period, safety was evaluated in 4,203 patients treated with ENTRESTO and 4,229 treated with enalapril. In PARADIGM-HF, patients randomized to ENTRESTO received treatment for up to 4.3 years, with a median duration of exposure of 24 months; 3,271 patients were treated for more than one year. Discontinuation of therapy because of an adverse event during the double-blind period occurred in 450 (10.7%) of ENTRESTO treated patients and 516 (12.2%) of patients receiving enalapril.Adverse reactions occurring at an incidence of ≥5% in patients who were treated with ENTRESTO in the double-blind period are shown in Table 1.Table 1: Adverse Reactions Reported in ≥5% of Patients Treated with ENTRESTO in the Double-Blind PeriodENTRESTO (n = 4,203)% Enalapril (n = 4,229)%Hypotension 1812 Hyperkalemia 1214 Cough 913 Dizziness 65Renal failure/acute renal failure 5 5In the PARADIGM-HF trial, the incidence of angioedema was 0.1% in both the enalapril and ENTRESTO run-in periods. In the double-blind period, the incidence of angioedema was higher in patients treated with ENTRESTO than enalapril (0.5% and 0.2%, respectively). The incidence of angioedema in Black patients was 2.4% with ENTRESTO and 0.5% with enalapril [see Warnings and Precautions (5.2)].Orthostasis was reported in 2.1% of patients treated with ENTRESTO compared to 1.1% of patients treated with enalapril during the double-blind period of PARADIGM-HF. Falls were reported in 1.9% of patients treated with ENTRESTO compared to 1.3% of patients treated with enalapril.Laboratory AbnormalitiesHemoglobin and HematocritDecreases in hemoglobin/hematocrit of >20% were observed in approximately 5% of both ENTRESTO- and enalapril-treated patients in the double-blind period in PARADIGM-HF.Serum CreatinineIncreases in serum creatinine of >50% were observed in 1.4% of patients in the enalapril run-in period and 2.2% of patients in the ENTRESTO run-in period. During the double-blind period, approximately 16% of both ENTRESTO- and enalapril-treated patients had increases in serum creatinine of >50%.Serum PotassiumPotassium concentrations >5.5 mEq/L were observed in approximately 4% of patients in both the enalapril and ENTRESTO run-in periods. During the double-blind period, approximately 16% of both ENTRESTO- and enalapril-treated patients had potassium concentrations >5.5 mEq/L.INTERACTIONS7 DRUG7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone SystemConcomitant use of ENTRESTO with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4)].Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the angiotensin II receptor blocker valsartan. The concomitant use of ENTRESTO with aliskiren is contraindicated in patients with diabetes [see Contraindications (4)]. Avoid use with aliskiren in patients with renal impairment (eGFR <60 mL/min/1.73 m²).Diuretics7.2 Potassium-SparingAs with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2Inhibitors)In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, concomitant use of NSAIDs, including COX-2 inhibitors, with ENTRESTO may result in worsening of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically.7.4 LithiumIncreases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use with ENTRESTO.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyRisk SummaryENTRESTO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. In animal reproduction studies, ENTRESTO treatment during organogenesis resulted in increased embryo-fetal lethality in rats and rabbits and teratogenicity in rabbits. When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO. However, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus.The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.Clinical ConsiderationsFetal/Neonatal Adverse ReactionsOligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of gestation. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. If oligohydramnios is observed, consider alternative drug treatment. Closely observe neonates with histories of in utero exposure to ENTRESTO for hypotension, oliguria, and hyperkalemia. In neonates with a history of in utero exposure to ENTRESTO, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function.DataAnimal DataENTRESTO treatment during organogenesis resulted in increased embryo-fetal lethality in rats at doses ≥ 49 mg sacubitril/51 mg valsartan/kg/day (≤ 0.14 [LBQ657, the active metabolite] and 1.5 [valsartan]-fold the maximum recommended human dose [MRHD] of 97/103 mg twice-daily on the basis of the area under the plasma drug concentration-time curve [AUC]) and rabbits at doses ≥ 5 mg sacubitril/5 mg valsartan/kg/day (4-fold and 0.06-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively). ENTRESTO is teratogenic based on a low incidence of fetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at an ENTRESTO dose of ≥ 5 mg sacubitril/5 mg valsartan/kg/day. The adverse embryo-fetal effects of ENTRESTO are attributed to the angiotensin receptor antagonist activity.Pre- and postnatal development studies in rats at sacubitril doses up to 750 mg/kg/day (4.5-fold the MRHD on the basis of LBQ657 AUC) and valsartan at doses up to 600 mg/kg/day (0.86-fold the MRHD on the basis of AUC) indicate that treatment with ENTRESTO during organogenesis, gestation and lactation may affect pup development and survival.8.2 LactationRisk SummaryThere is no information regarding the presence of sacubitril/valsartan in human milk, the effects on the breastfed infant, or the effects on milk production. Sacubitril/valsartan is present in rat milk. Because of the potential for serious adverse reactions in breastfed infants from exposure to sacubitril/valsartan, advise a nursing woman that breastfeeding is not recommended during treatment with ENTRESTO.DataFollowing an oral dose (15 mg sacubitril/15 mg valsartan/kg) of [14C] ENTRESTO to lactating rats, transfer of LBQ657 into milk was observed. After a single oral administration of 3 mg/kg [14C] valsartan to lactating rats, transfer of valsartan into milk was observed.Use8.4 PediatricSafety and effectiveness in pediatric patients have not been established.8.5 Geriatric UseNo relevant pharmacokinetic differences have been observed in elderly (≥65 years) or very elderly (≥75 years) patients compared to the overall population [see Clinical Pharmacology (12.3)].8.6 HepaticImpairmentNo dose adjustment is required when administering ENTRESTO to patients with mild hepatic impairment (Child-Pugh A classification).The recommended starting dose in patients with moderate hepatic impairment (Child-Pugh B classification) is 24/26 mg twice daily. The use of ENTRESTO in patients with severe hepatic impairment (Child-Pugh C classification) is not recommended, as no studies have been conducted in these patients [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].Impairment8.7 RenalNo dose adjustment is required in patients with mild (eGFR 60 to 90 mL/min/1.73 m2) to moderate (eGFR 30 to 60mL/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) is 24/26 mg twice daily [see Dosage and Administration (2.3), Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].10 OVERDOSAGELimited data are available with regard to overdosage in human subjects with ENTRESTO. In healthy volunteers, a single dose of ENTRESTO 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated.Hypotension is the most likely result of overdosage due to the blood pressure lowering effects of ENTRESTO. Symptomatic treatment should be provided.ENTRESTO is unlikely to be removed by hemodialysis because of high protein binding.11 DESCRIPTIONENTRESTO (sacubitril and valsartan) is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker. ENTRESTO contains a complex comprised of anionic forms of sacubitril and valsartan, sodium cations, and water molecules in the molar ratio of 1:1:3:2.5, respectively. Following oral administration, the complex dissociates into sacubitril (which is further metabolized to LBQ657) and valsartan. The complex is chemically described as Octadecasodiumhexakis(4-{[(1S,3R)-1-([1,1´-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)hexakis(N-pentanoyl-N-{[2´-(1H-tetrazol-1-id-5-yl)[1,1´-biphenyl]-4-yl]methyl}-L-valinate)—water(1/15).Its empirical formula (hemipentahydrate) is C48H55N6O8Na3 2.5 H2O. Its molecular mass is 957.99 and its schematic structural formula is:ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg ofvalsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The tablet inactive ingredients are microcrystalline cellulose, low-substituted hydroxypropylcellulose, crospovidone, magnesium stearate (vegetable origin), talc, and colloidal silicon dioxide. The film-coat inactive ingredients are hypromellose, titaniumdioxide (E 171), Macrogol 4000, talc, and iron oxide red (E 172). The film-coat for the 24 mg of sacubitril and 26 mg of valsartan tablet and the 97 mg of sacubitril and 103 mg of valsartan tablet also contains iron oxide black (E 172). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E 172).12 CLINICAL PHARMACOLOGY12.1 Mechanism of ActionENTRESTO contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. ENTRESTOinhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT 1) receptor via valsartan. The cardiovascular and renal effects of ENTRESTO in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT 1 receptor, and also inhibits angiotensin II-dependent aldosterone release. 12.2 PharmacodynamicsThe pharmacodynamic effects of ENTRESTO were evaluated after single and multiple dose administrations in healthy subjects and in patients with heart failure, and are consistent with simultaneous neprilysin inhibition and renin-angiotensin system blockade. In a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of ENTRESTO resulted in a significant non-sustained increase in natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP compared to valsartan .In a 21-day study in HFrEF patients, ENTRESTO significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1. ENTRESTO also blocked the AT 1-receptor as evidenced by increased plasma renin activity and plasma renin concentrations. In PARADIGM-HF, ENTRESTO decreased plasma NT-proBNP (not a neprilysin substrate) and increased plasma BNP (a neprilysin substrate) and urine cGMP compared with enalapril.QT Prolongation: In a thorough QTc clinical study in healthy male subjects, single doses of ENTRESTO 194 mg sacubitril/206 mg valsartan and 583 mg sacubitril/617 mg valsartan had no effect on cardiac repolarization.Amyloid-β: Neprilysin is one of multiple enzymes involved in the clearance of amyloid-β (A β) from the brain andcerebrospinal fluid (CSF). Administration of ENTRESTO 194 mg sacubitril/206 mg valsartan once-daily for 2 weeks to healthy subjects was associated with an increase in CSF A β1-38 compared to placebo; there were no changes inconcentrations of CSF A β1-40 or CSF A β1-42. The clinical relevance of this finding is unknown [see Nonclinical Toxicology(13)].Blood Pressure: Addition of a 50 mg single dose of sildenafil to ENTRESTO at steady state (194 mg sacubitril/206 mg valsartan mg once daily for 5 days) in patients with hypertension was associated with additional blood pressure (BP) reduction (~5/4 mmHg, systolic/diastolic BP) compared to administration of ENTRESTO alone.Co-administration of ENTRESTO did not significantly alter the BP effect of intravenous nitroglycerin.。

DA-662A系列硬件用户手册说明书

DA-662A系列硬件用户手册说明书

DA-662A Series Hardware User’s ManualEdition 2.0, September 2018/product© 2018 Moxa Inc. All rights reserved.DA-662A Series Hardware User’s Manual The software described in this manual is furnished under a license agreement and may be used only in accordance withthe terms of that agreement.Copyright Notice© 2018 Moxa Inc. All rights reserved.TrademarksThe MOXA logo is a registered trademark of Moxa Inc.All other trademarks or registered marks in this manual belong to their respective manufacturers.DisclaimerInformation in this document is subject to change without notice and does not represent a commitment on the part of Moxa.Moxa provides this document as is, without warranty of any kind, either expressed or implied, including, but not limited to, its particular purpose. Moxa reserves the right to make improvements and/or changes to this manual, or to the products and/or the programs described in this manual, at any time.Information provided in this manual is intended to be accurate and reliable. However, Moxa assumes no responsibility for its use, or for any infringements on the rights of third parties that may result from its use.This product might include unintentional technical or typographical errors. Changes are periodically made to the information herein to correct such errors, and these changes are incorporated into new editions of the publication.Technical Support Contact Information/supportMoxa AmericasToll-free: 1-888-669-2872 Tel: +1-714-528-6777 Fax: +1-714-528-6778Moxa China (Shanghai office) Toll-free: 800-820-5036Tel: +86-21-5258-9955 Fax: +86-21-5258-5505Moxa EuropeTel: +49-89-3 70 03 99-0 Fax: +49-89-3 70 03 99-99Moxa Asia-PacificTel: +886-2-8919-1230 Fax: +886-2-8919-1231Moxa IndiaTel: +91-80-4172-9088 Fax: +91-80-4132-1045Table of Contents1.Introduction ...................................................................................................................................... 1-1Overview ........................................................................................................................................... 1-2 Package Checklist ............................................................................................................................... 1-2 Product Features ................................................................................................................................ 1-2 Hardware Specifications ...................................................................................................................... 1-3 2.Hardware Introduction...................................................................................................................... 2-1Appearance ........................................................................................................................................ 2-2 DA-662A-8 ................................................................................................................................. 2-2DA-662A-16 ............................................................................................................................... 2-2 Dimensions ........................................................................................................................................ 2-3 Hardware Block Diagram ..................................................................................................................... 2-3 DA-66A-8 ................................................................................................................................... 2-3DA-662A-16 ............................................................................................................................... 2-4 LED Indicators .................................................................................................................................... 2-4 Reset Button ...................................................................................................................................... 2-4 LCD Screen ........................................................................................................................................ 2-5 Push Buttons ...................................................................................................................................... 2-5 Real-time Clock .................................................................................................................................. 2-5 3.Hardware Connection Description ..................................................................................................... 3-1Placement Options .............................................................................................................................. 3-2 Rack Mounting ............................................................................................................................ 3-2 Connecting the Hardware..................................................................................................................... 3-2 Wiring Requirements ................................................................................................................... 3-2Connecting the Power .................................................................................................................. 3-2Connecting to the Network ........................................................................................................... 3-3Connecting to a Serial Device ....................................................................................................... 3-3Configurable Pull High/Low Resistors for the RS-485 Port ................................................................. 3-4Connecting to the Console Port ..................................................................................................... 3-5USB Host.................................................................................................................................... 3-5CompactFlash ............................................................................................................................. 3-51Introduction The DA-662A series embedded computers come with 8 to 16 software selectable RS-232/422/485 serial ports, making them suitable for a variety of industrial applications. Models are available with 4 10/100 Mbps Ethernet ports. The DA-662A series model also comes with CF and USB ports to make it easy to add additional storage space. The computers are designed with a standard 19-inch, rugged 1U rackmount case, and are embedded with a 100-240 VAC power input. This combination of features gives users a robust and reliable ready-to-run solution for applications such as data acquisition and power substations.The following topics are covered in this chapter:❒Overview❒Package Checklist❒Product Features❒Hardware SpecificationsOverviewThe DA-662A series are RISC-based, ready-to-run embedded computers designed for industrial dataacquisition applications. Each model has 8 or 16 RS-232/422/485 serial ports, and 2 USB hosts based on the Moxa Macro 500 MHz communication processor. The DA-662A series has 4 Ethernet ports. The casing is astandard 1U, 19-inch wide rack-mounted rugged enclosure. The robust, rack-mountable mechanism design provides the hardened protection needed for industrial environment applications, and makes it easy for users to install the DA-662A series on a standard 19-inch rack. The DA-662A series are ideal for applications that require a distributed embedded technology, such as SCADA systems, plant floor automation, and powerelectricity monitoring applications.The DA-662A series are suitable for IT control room applications, the critical assets used in the control andautomation system of industrial plant floors, and in electric power utility substations. The DA-662A series can accept a wide range of power inputs (from 100 to 240V), which means that they can be connected to AC power lines. Because of the no hard disk, fan-less, energy efficient design, the DA-662A series minimize heatgeneration, can operate around the clock, year in and year out, in heavy duty, harsh industrial environments, delivering the kind of reliable computing power expected of a multifunctional controller.Choose from models of the DA-662A series that come pre-installed with the open-standard Linux OS. Thebuilt-in SDK makes program development easy by allowing you to follow the common programmingprocedures used on a standard PC. All of the software you develop for your own applications can be stored in the onboard Flash memory. The DA-662A series embedded computers are ideal for creating control systems with distributed architecture that are based on embedded technologies. Typical applications include SCADAsystems, plant floor automation, and power electricity monitoring.Package ChecklistBefore installing the DA-662A series, verify that the package contains the following items:• 1 DA-662A series embedded computer• 6 jumper caps•19-inch Rackmount Kit with 2 L-shaped metal plates and 8 screws•Ethernet Cable: RJ45-to-RJ45 cross-over cable, 100 cm•CBL-RJ45M9-150: RJ45-to-DB9 male serial port cable, 150 cm•CBL-RJ45F9-150: RJ45-to-DB9 female console port cable, 150 cm•Quick installation guide•Documentation and software CD•Warranty cardNOTE: Notify your sales representative if any of the above items are missing or damaged.Product Features•Moxa Macro 500 MHz Processor•On-board 128 MB RAM, 32 MB Flash ROM•8 to 16 RS-232/422/485 serial ports• 4 10/100 Mbps Ethernet•Standard 19-inch rack-mount installation, 1U height•Wide range of power input voltages from 100 to 240VAC•LCD screen and push buttons for Human-Machine Interface (HMI)•Ready-to-run Linux platform•Robust, fanless designHardware SpecificationsComputerCPU: MoxaMacro 500 MHzOS: Embedded Linux (pre-installed)DRAM: 128 MB onboardFlash: 32 MB onboardEthernet InterfaceLAN: 4 auto-sensing 10/100 Mbps ports (RJ45)Magnetic Isolation Protection: 1.5 kV built-inSerial InterfaceSerial Standards: 8 to 16 RS-232/422/485 ports, software selectable (8-pin RJ45)ESD Protection: 8 kV contact, 15 kV Air ESD protection for all signalsSurge Protection: 2 kV line-to-line and 4 kV line-to-ground surge protection, 8/20 μs waveform(DA-662A-I-8/16-LX only)Insulation: 500 V (DA-662A-I-8/16-LX only)Isolation: 2 kV digital isolation (DA-662A-I-8/16-LX only)Termination Resistor: 120 ohm, jumper selectableConsole Port: RS-232 (all signals), RJ45 connectorSerial Communication ParametersData Bits: 5, 6, 7, 8Stop Bits: 1, 1.5, 2Parity: None, Even, Odd, Space, MarkFlow Control: RTS/CTS, XON/XOFF, ADDC® (automatic data direction control) for RS-485Baudrate: 50 bps to 921.6 Kbps (supports non-standard baudrates; see user’s manual for details)Serial SignalsRS-232: TxD, RxD, DTR, DSR, RTS, CTS, DCD, GND(DA-662A-I-8/16-LX only: TxD, RxD, RTS, CTS, GND)RS-422: TxD+, TxD-, RxD+, RxD-, GNDRS-485-4w: TxD+, TxD-, RxD+, RxD-, GNDRS-485-2w: Data+, Data-, GNDLEDsSystem: OS ReadyLAN: 10/100M x 4Serial: TxD, RxD (8 to 16 of each)Mini Screen with Push ButtonsLCD Panel: Liquid Crystal Display on the case, 2 x 16 text modePush Buttons: Four membrane buttons for convenient on-site configurationPhysical CharacteristicsHousing: SECC sheet metal (1 mm)Weight: 4.3 kgDimensions:Without ears: 440 x 45 x 237 mm (17.32 x 1.77 x 9.33 in)With ears: 480 x 45 x 237 mm (18.90 x 1.77 x 9.33 in)Mounting: Standard 19-inch rackmountEnvironmental LimitsOperating Temperature: -10 to 60°C (14 to 140°F)Storage Temperature: -20 to 70°C (-4 to 158°F)Ambient Relative Humidity: 5 to 95% (non-condensing)Anti-Vibration: 1 g @ IEC-68-2-6, sine wave (resonance search), 5-500 Hz, 1 Oct/min, 1 Cycle, 13 mins 17 sec per axisPower RequirementsInput Voltage: 100 to 240 VAC auto ranging(47 to 63 Hz for AC input)Power Consumption: 20 WStandards and CertificationsSafety: UL 60950-1EMC:EN 55022/24CISPR 22, FCC Part 15B Class AIEC 61000-4-2 ESD: Contact 8 kV; Air 15 kVIEC 61000-4-3 RS: 3 V/m (80 MHz to 1 GHz)IEC 61000-4-4 EFT: Power 1 kV; Signal 0.5 kVIEC 61000-4-5 Surge: Power 2 kV; Signal 4 kVIEC 61000-4-6 CS: 3 VIEC 61000-4-8IEC 61000-4-11Green Product: RoHS, CRoHS, WEEEReliabilityAlert Tools: Built-in buzzer and RTC (real-time clock) Automatic Reboot Trigger: Built-in WDT (watchdog timer) MTBF (mean time between failures): 125,733 hrs WarrantyWarranty Period: 5 yearsDetails: See /warranty2Hardware Introduction DA-662A series hardware is compact, well-designed, and built rugged for industrial applications. LED indicators help you monitor the performance and identify trouble spots. Multiple ports allow the connection of different devices for wireless operation. With the reliable and stable hardware platform that is provided, you may devote your attention to the development of your application. In this chapter, learn the basics about the embedded computer hardware and its different parts.The following topics are covered in this chapter:❒AppearanceDA-662A-8DA-662A-16❒Dimensions❒Hardware Block DiagramDA-66A-8DA-662A-16❒LED Indicators❒Reset Button❒LCD Screen❒Push Buttons❒Real-time ClockAppearance DA-662A-8Front ViewRear ViewDA-662A-16Front ViewRear ViewDimensionsHardware Block DiagramThe following block diagrams show the layout of the DA-662A series’ internal components. DA-66A-8DA-662A-16LED IndicatorsLED indicators are located on the front panel of the DA-662A series. LED Name LED Color LED FunctionReady Red Power is On, and system is ready (after booting up) LAN1, LAN2, LAN3, LAN4 Orange10 Mbps Ethernet connection Green 100 Mbps Ethernet connectionP1-P16 (Rx) Orange Serial port is receiving RX data from the serial device Off Serial port is not receiving RX data from the serial device P1-P16 (Tx)Green Serial port is transmitting TX data to the serial device OffSerial port is transmitting TX data to the serial deviceReset ButtonPress the Reset button on the front panel continuously for at least 5 seconds to load the factory default configuration . After the factory default configuration has been loaded, the system will reboot automatically. The Ready LED will blink on and off for the first 5 seconds, and then maintain a steady glow once the system has rebooted.We recommend that you only use this function if the software is not working properly and you want to load factory default settings. To reset an embedded Linux system, always use the software reboot command />reboot to protect the integrity of data being transmitted or processed. The Reset button is not designed to hard reboot the DA-662A series.LCD ScreenThe DA-662A series has an LCD screen on the front panel. The LCD screen can display 16 columns and 2 rows of text. After the DA-662A series boots up, the LCD screen will display the model name and firmware version:D A - 6 6 2 A - 1 6 VER.1.Push ButtonsThere are four push buttons on the DA-662A series’ front panel. The buttons are used to enter text onto the LCD screen. The buttons are MENU, (up cursor),(down cursor), and SEL:Button ActionMENU Displays the main menu.Scrolls up through a list of items shown on the LCD screen’s second line.Scrolls down through a list of items shown on the LCD screen’s second line. SELSelects the option listed on the LCD screen.Real-time ClockThe DA-662A series’ real time clock is powered by a lithium battery. We strongly recommend that you do not replace the lithium battery without help from a qualified Moxa support engineer. If you need to change the battery, contact the Moxa RMA service team.3 Hardware Connection DescriptionThe following topics are covered in this chapter:❒Placement OptionsRack Mounting❒Connecting the HardwareWiring RequirementsConnecting the PowerConnecting to the NetworkConnecting to a Serial DeviceConfigurable Pull High/Low Resistors for the RS-485 PortConnecting to the Console PortUSB HostCompactFlashPlacement OptionsRack MountingThe DA-662A series is designed to be mounted on a standard 19-inch rack. Two L-shaped metal plates areincluded as standard accessories with the DA-662A series. Use the enclosed pair of L-shaped metal plates and screws to fasten your DA-662A series to the rack cabinet. Two placement options are available. You can either lock the front or the rear panel of the DA-662A series to the front of the rack. Each L-shaped plate has 6 holes, leaving two outer or inner holes open for your convenience.Connecting the HardwareThis section describes how to connect the DA-662A series to serial devices. The topics covered in this section are: Wiring Requirements, Connecting the Power, Connecting to the Network, Connecting to aSerial Device, and Connecting to the Console Port.Wiring RequirementsYou should observe the following common wiring rules:•Use separate paths to route wiring for power and devices. If power wiring and device wiring paths must cross, make sure the wires are perpendicular at the intersection point.NOTE: Do not run signal or communication wiring and power wiring in the same wire conduit. To avoidinterference, wires with different signal characteristics should be routed separately.•You can use the type of signal transmitted through a wire to determine which wires should be kept separate.The rule of thumb is that wiring that shares similar electrical characteristics can be bundled together.•Keep input wiring and output wiring separate.•Where necessary, it is strongly advised that you label wiring to all devices in the system. Connecting the PowerTo power on the DA-662A series, use a power cord to connect the power line to the DA-662A series’ AC power connector. The power connector is located on the right side of the rear panel. Next, turn on the power switch.The DA-662A series takes about 30 seconds to boot up. Once the device is ready, the Ready LED on the front panel will light up, and the DA-662A series model name and firmware version will appear on the LCD screen.Connecting to the NetworkFor DA-662A series, connect one end of the Ethernet cable to one of the DA-662A series’ 10/100M Ethernet ports (8-pin RJ45) and the other end of the cable to the Ethernet network. If the cable is properly connected, the DA-662A series will indicate a valid connection to the Ethernet in the following ways:Pin Signal 1 ETx+ 2 ETx- 3 ERx+ 4 – 5 – 6 ERx- 7 – 8–Connecting to a Serial DeviceUse properly wired serial cables to connect the DA-662A series to serial devices. The DA-662A series’ serial ports (P1 to P16) use 8-pin RJ45 connectors. The ports can be configured by software for RS-232, RS-422, or 2-wire RS-485. The pin assignments are shown in the following table:PinRS-232 RS-232(DA-662A-I-8/16-LX only)RS-422RS-4851 DSR – – –2 RTS RTS TXD+ –3 GND GND GND GND4 TXD TXD TXD- –5 RXD RXD RXD+ Data+6 DCD – RXD- Data-7 CTS CTS – – 8DTR–––Configurable Pull High/Low Resistors for the RS-485 PortIn some critical environments, you may need to add termination resistors to prevent the reflection of serialsignals. When using termination resistors, it is important to set the pull high/low resistors correctly so that the electrical signal is not corrupted. The DA-662A series uses jumper settings to set the termination resistors and pull high/low resistor values for each serial port.To configure the termination or pull high/low resistors, you first need to open the DA-662A's chassis. You will see 3 rows of jumper caps (as shown in the accompanying figure). The first row is for setting pull high resistors, the second row is for setting termination resistors, and the third row is for setting pull low resistors.Each serial port has 6 jumper caps for configuring the resistors. The pin assignments are shown in the following table:Jumper settingRS485 Data + RS485 Data -Pull High resistors1-2: 150 kΩ2-3: 1 kΩTermination1-2: Open2-3: 120 ΩPull Low resistors1-2: 150 kΩ2-3: 1 kΩTo set the termination resistors to 120 Ω, make sure that PIN 2 and PIN 3 assigned to the serial port are shorted by jumper caps.To set the pull high/low resistors to 150 kΩ, make sure that PIN 1 and PIN 2 assigned to the serial port are shorted by jumper caps. This is the default setting.To set the pull high/low resistors to 1 kΩ, make sure that PIN 2 and PIN 3 assigned to the serial port are shorted by jumper caps.Connecting to the Console PortThe DA-662A series’ console port is an 8-pin RJ45 RS-232 port. The pin definition is the same as for the serial ports (P1 to P16).USB HostThe DA-662A series offers 2 USB 2.0 hosts, allowing you to connect with a USB storage device. The first USB mass storage device to be connected will be mounted automatically by mount to /mnt/sdc, and the second device will be mounted automatically to /mnt/sdd. The DA-662A series will be un-mounted automatically with the umount command when the device is disconnected.CompactFlashThe DA-662A series have a built-in CompactFlash socket. The CompactFlash socket allows users to addadditional memory by inserting a CompactFlash memory card, without any risk to the computer.Follow the instructions below to insert a CompactFlash card:1.Turn off DA-662A.2.Insert the CompactFlash card into the socket.3.Turn on DA-662A.。

DAServer

DAServer

Technical Information Sheet Page 1 of 10741-F Miller Drive Leesburg Virginia 20175 T +1 703 443-0000 F +1 703 669-1300 TIS#: 298Date: June 2, 2009Issued by: Mark DemickSubject How to use the Eurotherm’s Chessell 6000 Series Paperless Graphic DAQ Recorders with Wonderware’sDASMBTCP Server V1.5.Software and Hardware UsedEurotherm Chessell 6180A, V4.3 FirmwareWonderware OPCLink V8Wonderware InTouch V9.5Wonderware DASMBTCP V1.5 (0246.0186)Open Wonderware System Management Console; start/All Programs/Wonderware/System Management Console. If DASMBTCP is installed there is an ArchestrA.DASMBTCP.1 folder in the DAServer manager hierarchy tree as shown in Figure 1.Figure 1 Archestra HierarchyThe server specific configuration portion of the MBTCP server starts by adding a TCPCIP_PORT object byright clicking on Configuration and selecting Add TCPIP_PORT Object. The default port name isNew_TCPIP_PORT_000 that can be changed to something more informative. This is shown in Figure 2 where the TCPIP_PORT has been renamed to TCPIP1.Leave the Port number default of 502 as is.Figure 2 Adding TCPIP_PORT ObjectTo complete the configuration endpoint hierarchy add a ModbusPLC object to the TCPIP_PORT object. There are other Modbus controller objects that can be created at this hierarchical level, however, the ModbusPLC object represents the generic 4, 5 or 6-digit controller to which the Eurotherm recorders and controllers are compatible. For the 6000 Series recorder, the addressing is 6-digit.Add a ModbusPLC object as shown in Figure 3 for each recorder on the network that has a unique IP Address. The default name is New_ModbusPLC_000 and may be changed to something more informative.Figure 3 Adding a ModbusPLC ObjectFor the ModbusPLC object named F12_Chessell, the configuration shown in Figure 4, are the defaults except for the Network address that has been changed to that of the connected Chessell 6180A recorder and unchecking ‘Use Concept data structures (Reals) that is explained further on.Figure 4 Modbus PLC Object ParametersTo add a Device Group, select the Device Groups tab, right click anywhere in the cell areas and select Add as shown in Figure 5. Change the default Name from Topic_0 to a more meaningful name if desired.Figure 5 Modbus PLC Device Group ParametersIn the Device Items tab, item names and modbus addresses are entered. There are available integer and real (32-bit single precision)having defined absolute modbus addresses rather than register-number addressing for configuration and run-time data in the recorder. To determine the modbus address for the Device Items tab reference the 6100A/6180A User Guide, HA028910, Issue 6, available from the Eurotherm web sites. In the 6100A/6180A User Guide section 8 are the Modbus TCP Slave Comms address information.The integer channel run-time addresses are from section 8.4.3, Channel Run-Time data, while real channel run-time addresses are from section 8.4.8, IEEE Area Channel run-time data. Using Channel 1 as an example from thetable, ‘Ch1 value’ is listed with a modbus address of 41433. This is an absolute address and not the modbus address to be entered as the Item Reference in register-number format. The DASMBTCP server supports absolute notation item names through a suffix after the modbus address and register-number addressing.To convert from absolute to register-number addressing use the following formula:Register-number = 400000 + absolute address + 1Using the Ch1 value of 41433 and entering into the formula above we derive the register-number address of 441434 for Ch1.To add Device Items select the Device Items tab, right click anywhere in the cell areas and select Add. Enter in a name for the device item or tag. Then double click in the corresponding Item Reference cell to add the Modbus register-number address as shown in Figure 6. The Item Reference values can be in either register-number format as shown in Figure 6, or absolute address format as shown in Figure 7.Figure 6 Modbus PLC Device Items Parameters, Register-Number Addressing, IntegersThe Item Reference absolute address is straight from the 6100A/6180A User Guide with a suffix of HR (Holding Register). As the recorder does not distinguish between input or holding registers, the IR (Input Register) suffix may also be used.Figure 7 Modbus PLC Device Items Parameters, Absolute Addressing, IntegersThe above were examples of reading integer values from the recorder. To read real values from the recorder reference section 8.4.8, IEEE Area Channel run-time data, for the absolute Modbus address for the channel process values (PV). The real values consist of two (2) consecutive register values and the word order if not correct can cause the value to read or write incorrectly. From Figure 4, note that the ‘Use Concept data structure (Reals)’ has been unchecked. This changes the word order so that it is interpreted correctly.Again, either absolute or register-number addressing is supported. Figure 8 shows register-number addressing. Note the suffix ‘F’ to indicate that this is a real value telling the DASMBTCP driver to read two (2) words. The formula for converting real addresses to integer addresses is the same. The Ch1 real process value address is 63683. Using the same formula as for integers previously results in the Modbus register-number address of463684. Using absolute addressing requires either the suffix HRF or IRF that is a concatenation of Holding or Input Register with Float.Figure 8 Modbus PLC Device Items Parameters, Register-Number Addressing, IntegersFigure 9 Modbus PLC Device Items Parameters, Absolute Addressing, IntegersWhen reading integer values from the recorder, there is a parameter in the recorders Channel configuration that effects the position of the implicit decimal point. This is set by the ‘Max Decimal Digits’ parameter in a Channel’s Configuration. Only if the resulting value can be represented within 16 bit resolution (±32767), will the value be transmitted accurately.For example, with a Max Decimal Digits of 4 and a value of 12.3456, the integer value would be 123456 that needs more than 16-bit resolution, and the transmitted value would be the maximum value of 32767 (over range). Reducing the Max Decimal Digits number of decimal places to three (3) using our example number 12.3456, results in an integer value of 12345 which allows the value to be encoded as a 16-bit value which can be transmitted accurately.It can be seen then that the Max Decimal Digits parameter is a multiplier on the channel value that causes an implicit decimal point position in the Modbus values. For reads from the recorder, this implies that at the host device that the value needs to be divided by 10n where n is Max Decimal Digits.Figure 10 Max Decimal Digits.The DASMBTCP Server is an OPC Server. This means that any OPC Client can connect to the DASMBTCP Server. In Figure 11, the Eurotherm iTools OPC Scope client has been used to demonstrate an OPC Client connecting to the DASMBTCP Server.Two (2) items configured previously are shown receiving values in OPC Scope.Figure 11 iTools OPC ScopeTo use the DASMBTCP Server with InTouch, the Wonderware OPCLink Client needs to be configured to interface between InTouch and the DASMBTCP Server. This is because InTouch is not an OPC Client.Open OPCLink, create a New Configuration if required and configure one or more Topic Definitions.As shown in Figure 12, the Topic Name can be anything but typically descriptive of the instrument node, the OPC Server Name chosen from the drop-down and the OPC Path configured by clicking on the Browse button. This brings up the OPC Browser window as shown in Figure 13. You can see the TCPIP_Port and Modbus_PLC Objects defined in DASMBTCP Server. The OPC Path configured below includes both of those object names though it does not have to; e.g. the OPC Path could be TCPIP_PORT object name only. In any case, the remainder of the OPC Path name is entered during the definition of the tag in WindowMaker.Figure 12 OPCLink OPC Topic Definition Dialog BoxFigure 13 OPCLink OPC Browser Dialog BoxA tag in WondowMaker is created as shown in Figure 14. An Access Name has been created to point to the topic created in OPCLink and the tag name is the remainder of the fully qualified OPC path name. The ‘r’ prefix indicatesa real data type. Thus to concatenate the OPC Path from the topic in OPC Link and the tagname Item below you would have the fully qualified name ‘TCPIP1.F12_Chessell.Channel_1_PV_R’.Figure 14 Tagname Dictionary Tag DefinitionOn the Wonderware support web site is Tech Note 424, “Working with DAServers”, that contains more detailed information than the online help does.The examples shown within this document apply to more than just the 6000 Series recorders. They apply to any Eurotherm modbus/TCP slave recorder or controller.。

TL669(英)

TL669(英)

Polyethylene of High Molecular Weight, Finished Parts Material Requirements4 Types: without index, A, B, C Previous issuesTL 669: 1973-11, 1976-03, 1985-10, 1987-09, 1995-05, 2002-12ChangesThe following changes have been made as compared to TL 669: 2002-12:–Type C added–Referenced documents updated ScopeThis Technical Supply Specification defines the material requirements for finished parts made from polyethylene of high molecular weight, e.g., plastic fuel tanks and associated add-on and installation parts.DescriptionDescription example for the type manufactured using the Phillips polymerization process:PE of high molecular weight according to TL 669Requirements General requirementsApproval of first supply and changes according to Volkswagen standard VW 01155.Emission behavior according to VW 50180, if required in the drawing.Resistance to open-air weathering according to VW 50185.1233.1Group StandardTL 669Issue 2008-09Class. No.:55121DDescriptors:PE, polyethylene, plastic fuel tank, extrusion blow processCheck standard for current issue prior to usage.This electronically generated standard is authentic and valid without signature.The English translation is believed to be accurate. In case of discrepancies the German version shall govern.Numerical notation acc. to ISO practice.Page 1 of 6Technical responsibility Standards department GQL-LP/4Lars Fölster Tel.: +49-5361-9-24850GQL-LPDr. Roger HillertEKTC/4 Ute Hager-SüßEKTCTel.: +49-5361-9-49035Manfred TerlindenConfidential. All rights reserved. No part of this document may be transmitted or reproduced without prior permission of a Standards Department of the Volkswagen Group.Parties to a contract can only obtain this standard via the B2B supplier platform "".© VOLKSWAGEN AGVWNORM-2007-10fAvoidance of hazardous substances according to VW 91101.For plastic fuel tanks, 1 finished part is required for complete testing; for smaller finished parts, 10parts are required.QualityThe surface and interior (e.g., walls of the container) of the finished parts must not have any flaws such as cracks, blisters, voids, areas with an increased notch effect, foreign inclusions, and/or mold‐ing material particles that are insufficiently molten down during processing. Parts manufactured by means of injection molding, e.g., plastic fuel tank add-on and installed parts, must furthermore be free of flow lines and microstructural inhomogeneities, such as film and layer formation ("puff pas‐try" texture).Human compatibilityThe materials used must be physiologically safe. Substances that are emitted at elevated tempera‐tures must be toxicologically safe.ManufactureExtrusion blow or injection molding method Types–TL 669High molecular weight PE, manufactured according to the Phillips polymer‐ization process; suitable for the extrusion blow method.–TL 669-A High molecular weight PE, manufactured according to the Ziegler polymer‐ization process; suitable for the extrusion blow method.–TL 669-B High molecular weight PE, manufactured according to the Phillips polymer‐ization process; suitable for the injection molding method.–TL 669-CHigh molecular weight PE, manufactured according to the Ziegler polymer‐ization process; suitable for the injection molding method.Marking according to VDA 260All types: > PE-HD <AgingPrior to testing, the specimens required for the individual tests must be aged for at least 48 h in the DIN 50014 – 23/50-2 standard climate.Evaluation of measurement resultsUnless otherwise noted, the required numerical values apply to each individual measurement and to every point on the finished part.3.23.33.43.5 3.6 3.73.8Page 2TL 669: 2008-09DMaterial requirements MaterialSee Section 6.1.All types: Polyethylene of high molecular weight with stabilizer additive to protect against oxidation and aging.ColorAccording to drawing. Coloring must be uniform throughout.Required propertiesSee Table 1.Table 14 4.14.25Page 3TL 669: 2008-09DNotes on testing MaterialThe identity test can be performed by infrared spectroscopy or thermal analysis.6 6.1Page 4TL 669: 2008-09DYield stress and elongation at yieldTensile test according to DIN EN ISO 527-2, specimen 5A, test rate 50 mm/min.Behavior at high deformation rateFast tensile test on tensile impact specimens according to DIN EN ISO 8256, type 3; free clamping length of 40 mm; test rate of (6 ± 0,1) m/s; test equipment e.g. Zwick universal testing machine, type REL 1852. The change in the length of the specimens must be determined at a drop in force of 90%(= machine setting for break recognition). At least 5 specimens each from flat areas (in fuel tanks,preferably from the base area) must be tested.Elevated-temperature behaviorAging at elevated temperature test according to DIN 53497, method B, on at least 2 complete finished parts; aging temperature of (90 ± 1) °C; aging period of (22 + 2) h.Maximum shrinkageAging at elevated temperature test according to DIN 53497, method B, on square cutouts with an edge length of 50 mm. The cutouts are to be taken from the blow-molded part in such a way that two parallel edges of the square run exactly in the direction of extrusion. The edges of the cutouts must be measured to an accuracy of 0,1 mm before and after aging. A minimum of 3 specimens must be tested. Aging duration of (2 + 0,5) h; aging temperature of (128 ± 1) °C.Low-temperature behaviorAging of at least one complete finished part in air at (-40 ± 1) °C; aging period of (22 + 2) h.Resistance to stress crackingThe components must be equipped with original installation and add-on parts (e.g., pump, cover, etc.)and installed in this condition in a test device that simulates exactly the installation position in the vehicle. The tanks must be filled according to their nominal volume with a 10% aqueous solution of a non-ionogenic wetting agent (such as “Lutensol FSA 10” by BASF) and then aged in a forced ventilation oven at (80 ± 1) °C. Individual parts are immersed in the solution. The specimens are visually evaluated after the prescribed test duration has elapsed. A minimum of 3 parts must be tested.LightfastnessIf the number of exposure periods is not defined in the drawing, the following rule applies:– 3 periods of exposure for components in areas with indirect sun radiation.– 5 periods of exposure for components in areas with direct sun radiation (e.g., upper door trim).–10 periods of exposure for components in areas subject to the highest sun radiation (e.g., rear shelf).Type approvalThe requirement applies to new-sample and initial-sample deliveries (basic test of material suitability).Volkswagen AG reserves the right to draw on this for the evaluation of supplies for standard produc‐tion.6.26.36.46.56.66.76.86.9Page 5TL 669: 2008-09DReferenced documentsThe following documents cited in this standard are necessary for application.In this Section terminological inconsistencies may occur as the original titles are used.PV 1303Non-Metallic Materials; Exposure Test of Passenger Compartment Com‐ponentsTL 1010Materials for Vehicle Interiors; Burning Behavior; Material Requirements VW 01155Vehicle Supply Parts; Approval of First Supply and Changes VW 50180Components in Passenger Compartment; Emission Behavior VW 50185Vehicle Components; Resistance to Open Air WeatheringVW 91101Environmental Standard for Vehicles; Vehicle Parts, Materials, Operating Fluids; Avoidance of Hazardous Substances DIN 50014–DIN 53497Testing of Plastics; Hot Storage Test on Mouldings Made of Thermoplastic Moulding Materials without External Mechanical Stressing DIN 53505Testing of rubber - Shore A and Shore D hardness testDIN EN 20105-A02Textiles - Tests for colour fastness - Part A02: Grey scale for assessing change in colourDIN EN ISO 1133Plastics - Determination of the melt mass-flow rate (MFR) and the melt volume-flow rate (MVR) of thermoplasticsDIN EN ISO 1183-1Plastics - Methods for determining the density of non-cellular plastics - Part 1: Immersion method, liquid pyknometer method and titration method DIN EN ISO 527-2Plastics - Determination of tensile properties - Part 2: Test conditions for moulding and extrusion plasticsDIN EN ISO 8256Plastics - Determination of tensile-impact strengthISO 11357-3Plastics - Differential scanning calorimetry (DSC) - Part 3: Determination of temperature and enthalpy of melting and crystallization VDA 260Components of motor vehicles; marking of material7Page 6TL 669: 2008-09D。

CertificateofResidency

CertificateofResidency

CERTIFICATE OF RESIDENCEInformation and DirectionsFor Residents of New York CityA Certificate of Residence issued by your home county entitles you to pay the resident tuition fee to attend a community college in New York State and not the higher, non-resident tuition. The New York City Comptroller issues these certificates to qualified residents living within the five boroughs of New York City.The Certificate of Residence is EFFECTIVE FOR ONE YEAR from the date it is issued. You must apply for and submit a new Certificate of Residence to your college once a year, every year at the beginning of the semester (or quarter), along with your tuition payment. If you do not submit the Certificate of Residence, you will be charged the higher, non-resident tuition fee.RESIDENCY QUALIFICATIONS:▪Resident of New York State for at least one (1) year immediately prior to the date of application, and also▪Resident of New York City for at least six (6) months immediately prior to the date of application.Note: Members of the U.S Armed Forces, while on full-time active duty and stationed within New York State, and their spouses and dependents are eligible for the resident tuition rate.TO APPLY:All applicants (students) must provide two forms of proof to verify residency: ONE THAT IS DATED MORE THAN SIX MONTHS AGO AND ONE DATED LESS THAN SIX MONTHS AGO. Proof must show applicant's address (not P.O. Box or in care of a third party) and include the applicant's name.Examples of acceptable proof of residency are:▪lease or deed, or if not available, a letter from a landlord on the landlord's letterhead indicating dates of tenancy and rent payments▪postmarked envelope mailed to you at your current address, dated less than six (6) months ago▪prior year's income tax return (parents' or parent's tax return, if listed as dependent)▪homeowner's or renter's insurance policy▪driver's license or automobile registration certificate▪bank statement▪automobile insurance policy▪utility bill▪cell phone bill▪selective service card▪voter registration.Note: If residing with parent, you may bring one of the above proofs that show the permanent, New York City address of the parent/student residence, along with a letter signed by parent and notarized that states the student is now, and has been for a period of one year, living with that parent.Fill out the AFFADAVIT AND APPLICATION form (reverse side) and have it NOTARIZED. A Notary Public is available at the NY County Clerk's Office, 60 Centre Street, Room 141B, Mon. – Fri. from 9:00 AM – 5:00 PM.(Valid photo ID required.) The Comptroller's Office does not notarize.Present the original, NOTARIZED AFFIDAVIT plus the TWO ITEMS to prove residency in person to: Office of the New York City ComptrollerOne Centre Street (Municipal Building)Room 703, Certificate of Residence DeskNew York, NY 10007O pen ONLY during these hours: Mon. – Fri. 8:30 AM – 4:30 PM (Not open on weekends or holidays).Questions regarding the above may be directed to (212) 669-2784. The affidavit, information and directions are available at .。

最好的网址大全

最好的网址大全

&lt;&lt;最好的网址大全&gt;&gt;好123网址之家美萍中文网站精选265上网导航中国缘网址大全9991网址大全网址大全吧中国导航网址大全搜索天下网来看吧网址大全中文网址大全八仙居网址大全5566中国精彩网址www8网址吧855网址大全中国网址大全qu123网址大全网罗天下上网导航中国好网中国导航网全球网址之家V111网址大全ok321极品网址站800个性网址QQ网址大全中国精彩网址26800网址大全好友多网址大全好东西网址中国网址站13亿上网导航唯一ok导航网首页网友好界面网址889889网址之家51115网址大全516实用导航挑挑拣拣精品网址广捷居网址大全雅虎网址大全天天好上网导航CNWW-中国网址中华网址大全432网址精品网址导航37021酷站大全da123网址大全挑三拣四网址导航中国网址中华网址精品网址网址总汇0135网址大全华夏网址大全网址在线网址大全QQ网址大全35ok网址大全找网站离不开网址大全MSNCN中文网址大全TT网址大全第八色彩网址大全17zao网址大全网址大全网址大全航123网址大全网罗网址大全百度网址大全ha123网址大全OK383网址大全网站114银沙网址大全516789网址大全369万上网导航32abc网址精选中国网上黄页网址导航好站大全寻123网址大全中国通用网址yes165网址精选中文网址宝库好六网址大全黑虎精品网VVSO上网导航实用网址大全中文网址大全chinaeall网址大全亿路123网址大全goodsgy网址大全好友网网址大全万千网址大全好就要网址大全25小时网址大全8033网址导航道道道网址大全金豹网网址大全网易网址精选adaoz网址大全网址天下大家找实用站点大全828网址大全我爱找网址大全帮您导航网址大全连我精品网址导航3691网址大全实用网址大全互动生活在线网址大全笑吧网址大全网址大全好淘网址大全中国电子商务网网址大全博讯商务搜索--网址大全海内外网址大全晨曦网址大全快搜网址大全耕耘网网址大全PAT网址大全好狐网址大全中国网站大全上网大全网址大全我秀网网址大全网酷网址大全好网址大全万佳互动网址大全硇洲岛网址大全900Me上网导航全球网址之家x63叉63上网导航360行网站导航网址大全中国dmoz版经典网址大全812345中文网址大全中国网址之家中国好网网址123789网址大全点吧网址大全木屋网址导航一页搜址人人搜中文上网导航ok383中文网址大全321E网址大全Q不Q中文网114123网址大全7788网址大全中国网络报网址大全无忧酷网导航521521网址找网站找123大123网站大全百分百好站3tom专业网址大全太极网网址大全加加上网导航好看123百鸣网址大全网址大宝库94135酷站大全奇迹网址精选站老友网址找找看网址精选369e上网导航COC域名城网址大全鑫洋导航123上网导航名搜遍天下我上我网108du网址大全FM360网址通酷Q网址吧123goo上网导航中国门户68538上网导航爱我吧z126无搜网长宽网络站18300网址世界星星521网址大全搜九网址大全112345中文网址精选先锋酷站导航中华网址来搜吧网址大全网址吧百乐网址导航来456网址大全断情草网址导航中国网址库上网第一站上网之家874上网导航123hao查询网D100百强网址上网指南99510网址之家天天网址精选V669上网导航妹妹笑笑网址之家16263网址精选冰点上网导航中国网址之家hy网址大全百搜网址大全百搜网12319.855网址大全飞舞领航bbip网址之家免费资源网址站百度123搜索导航unwww搜索大全36531娱乐导航九搜网址导航好方便网址连我精品网址导航6117上网导航网讯热点网址精选九州上网导航酷126网址通通有。

说明书(LAMISIL)01

说明书(LAMISIL)01

permanent. Discontinue Lamisil Tablets if smell disturbance occurs. (5.3) Severe neutropenia has been reported. If the neutrophil count is < 1,000 xx/2012 FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE2 DOSAGE AND ADMINISTRATION3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND PRECAUTIONS 5.1 Hepatotoxicity 5.2 Taste Disturbance Including Loss of Taste 5.3 Smell Disturbance Including Loss of Smell 5.4 Depressive Symptoms 5.5 Hematologic Effects 5.6 Skin Reactions 5.7 Lupus Erythematosus 5.8 Laboratory Monitoring 6 ADVERSE REACTIONS 6.1 Clinical Studies Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions 7.2 Food Interactions 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal toxicology and/or pharmacology 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listedFULL PRESCRIBING INFORMATION1 INDICATIONS AND USAGELamisil (terbinafine hydrochloride) Tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis.4 CONTRAINDICATIONSLamisil Tablets are contraindicated in individuals with a history of allergic reaction to oral terbinafine because of the risk of anaphylaxis.5 WARNINGS AND PRECAUTIONS5.1 HepatotoxicityCases of liver failure, some leading to liver transplant or death, have occurred with the use of Lamisil Tablets in individuals with and without pre-existing liver disease.In the majority of liver cases reported in association with Lamisil use, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease. Treatment with Lamisil Tablets should be discontinued if biochemical or clinical evidence of liver injury develops.Lamisil Tablets are not recommended for patients with chronic or active liver disease. Before prescribing Lamisil Tablets, pre-existing liver disease should be assessed. Hepatotoxicity may occur in patients with and without pre-existing liver disease. Patients prescribed Lamisil Tablets should be warned to report immediately to their physician any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine or pale stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’s liver function should be immediately evaluated.5.2 Taste Disturbance Including Loss of TasteTaste disturbance, including taste loss, has been reported with the use of Lamisil Tablets. It can be severe enough to result in decreased food intake, weight loss, and depressive symptoms. Taste disturbance may resolve within several weeks after discontinuation of treatment, but may be prolonged (greater than one year), or may be permanent. If symptoms of a taste disturbance occur, Lamisil Tablets should be discontinued.5.3 Smell Disturbance Including Loss of SmellSmell disturbance, including loss of smell, has been reported with the use of Lamisil Tablets. Smell disturbance may resolve after discontinuation of treatment, but may be prolonged (greater than one year), or may be permanent. If symptoms of a smell disturbance occur, Lamisil Tablets should be discontinued.5.4 Depressive SymptomsDepressive symptoms have occurred during postmarketing use of terbinafine. Prescribers should be alert to depressivesymptoms, and patients should be instructed to report depressive symptoms to their physician.5.5 Hematologic EffectsTransient decreases in absolute lymphocyte counts (ALC) have been observed in controlled clinical trials. In placebo-controlled trials, 8/465 Lamisil-treated patients (1.7%) and 3/137 placebo-treated patients (2.2%) had decreases in ALC tobelow 1000/mm3 on two or more occasions. In patients with known or suspected immunodeficiency, physicians shouldconsider monitoring complete blood counts if treatment continues for more than six weeks. Cases of severe neutropeniahave been reported. These were reversible upon discontinuation of Lamisil, with or without supportive therapy. If clinicalsigns and symptoms suggestive of secondary infection occur, a complete blood count should be obtained. If the neutrophilcount is <1,000 cells/mm3, Lamisil should be discontinued and supportive management started.5.6 Skin ReactionsThere have been postmarketing reports of serious skin reactions (e.g., Stevens-Johnson Syndrome and toxic epidermal necrolysis). If progressive skin rash occurs, treatment with Lamisil Tablets should be discontinued.5.7 Lupus ErythematosusDuring post-marketing experience, precipitation and exacerbation of cutaneous and systemic lupus erythematosus havebeen reported in patients taking Lamisil Tablets. Lamisil Tablets should be discontinued in patients with clinical signs and symptoms suggestive of lupus erythematosus.5.8 Laboratory MonitoringMeasurement of serum transaminases (ALT and AST) is advised for all patients before taking Lamisil Tablets.6 ADVERSE REACTIONS6.1 Clinical Studies ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drugcannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The most frequently reported adverse events observed in the three US/Canadian placebo-controlled trials are listed in thetable below. The adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia, andabdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. Changes in the ocular lens andretina have been reported following the use of Lamisil Tablets in controlled trials. The clinical significance of thesechanges is unknown. In general, the adverse events were mild, transient, and did not lead to discontinuation from study participation.Adverse Event DiscontinuationLamisil Placebo Lamisil Placebo(%) (%) (%) (%)n=465 n=137 n=465 n=1379.5 0.2 0.0 Headache 12.9Gastrointestinal Symptoms:Diarrhea 5.6 2.9 0.6 0.0 Dyspepsia 4.3 2.9 0.4 0.02.4 1.5 0.4 0.0PainAbdominalNausea 2.6 2.9 0.2 0.0Flatulence 2.2 2.2 0.0 0.0Dermatological Symptoms:Rash 5.6 2.2 0.9 0.7Pruritus 2.8 1.5 0.2 0.0 Urticaria 1.1 0.0 0.0 0.0Liver Enzyme 3.3 1.4 0.2 0.0 Abnormalities*2.8 0.7 0.2 0.0DisturbanceTasteVisual Disturbance 1.1 1.5 0.9 0.0* Liver enzyme abnormalities ≥2x the upper limit of normal range.6.2 Postmarketing ExperienceThe following adverse events have been identified during post-approval use of Lamisil. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Adverse events, based on worldwide experience with Lamisil Tablets use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions (e.g., Stevens-Johnson Syndrome and toxic epidermal necrolysis), severe neutropenia, thrombocytopenia, agranulocytosis, pancytopenia, anemia, angioedema, and allergic reactions (including anaphylaxis) [see Warnings and Precautions (5.1, 5.5 , and 5.6)].Psoriasiform eruptions or exacerbation of psoriasis, acute generalized exanthematous pustulosis and precipitation and exacerbation of cutaneous and systemic lupus erythematosus have been reported in patients taking Lamisil [see Warnings and Precautions (5.7)].Cases of taste disturbance, including taste loss, have been reported with the use of Lamisil Tablets. It can be severe enough to result in decreased food intake, weight loss, and depressive symptoms [see Warnings and Precautions (5.2)]. Depressive symptoms independent of taste disturbance have been reported with use of Lamisil Tablets. In some cases, depressive symptoms have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy [see Warnings and Precautions (5.4)]. Cases of smell disturbance, including smell loss, have been reported with the use of Lamisil Tablets [see Warnings and Precautions (5.3)].Other adverse reactions which have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, rhabdomyolysis, reduced visual acuity, visual field defect, hair loss, serum sickness-like reaction, vasculitis, pancreatitis, influenza-like illness, pyrexia, increased blood creatine phosphokinase, photosensitivity reactions, tinnitus, hearing impairment and vertigo.Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin has been reported.7 DRUG INTERACTIONS7.1 Drug-Drug InteractionsIn vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of Lamisil should be done with careful monitoring and may require a reduction in dose of the2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in C max and a 5-fold increase in AUC. In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of Lamisil Tablets. In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/dextrorphan metabolite ratio in urine by 16- to 97­fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolizers to poor metabolizer status.In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin. In vivo drug-drug interaction studies conducted in healthy volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by 15%.The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant.Co-administration of a single dose of fluconazole (100mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine C max and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (C max and AUC) of terbinafine when concomitantly administered. There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between Lamisil Tablets and these changes has not been established.Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine. There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers.7.2 Food InteractionsAn evaluation of the effect of food on Lamisil Tablets was conducted. An increase of less than 20% of the AUC (i.e. area under the curve) of terbinafine was observed when Lamisil Tablets were administered with food. Lamisil Tablets can be taken with or without food.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Category B: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that Lamisil not be initiated during pregnancy.Oral reproduction studies have been performed in rabbits and rats at doses up to 300 mg/kg/day (12x to 23x the MRHD, in rabbits and rats, respectively, based on BSA) and have revealed no evidence of impaired fertility or harm to the fetus due to terbinafine.8.3 Nursing MothersAfter oral administration, terbinafine is present in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:1. Treatment with Lamisil is not recommended in nursing mothers.8.4 Pediatric UseThe safety and efficacy of Lamisil Tablets have not been established in pediatric patients with onychomycosis.8.5 Geriatric UseClinical studies of Lamisil Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.10 OVERDOSAGEClinical experience regarding overdose with oral terbinafine is limited. Doses up to 5 grams (20 times the therapeutic daily dose) have been taken without inducing serious adverse reactions. The symptoms of overdose included nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache.11 DESCRIPTIONLamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26CIN with a molecular weight of 327.90, and the following structural formula:Terbinafine hydrochloride is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.Each tablet contains:Active Ingredients: terbinafine hydrochloride (equivalent to 250 mg base)Inactive Ingredients: colloidal silicon dioxide NF, hydroxypropyl methylcellulose USP, magnesium stearate NF, microcrystalline cellulose NF, and sodium starch glycolate NF.12 CLINICAL PHARMACOLOGY12.1 Mechanism of ActionTerbinafine is an allylamine antifungal [see Clinical Pharmacology (12.4)].12.2 PharmacodynamicsThe pharmacodynamics of Lamisil is unknown.12.3 PharmacokineticsFollowing oral administration, terbinafine is well absorbed (>70%) and the bioavailability of Lamisil Tablets as a result of first-pass metabolism is approximately 40%. Peak plasma concentrations of 1 µg/mL appear within 2 hours after a single 250 mg dose; the AUC (area under the curve) is approximately 4.56 µg.h/mL. An increase in the AUC of terbinafine of less than 20% is observed when Lamisil Tablets are administered with food.In plasma, terbinafine is >99% bound to plasma proteins and there are no specific binding sites. At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours. Terbinafine is distributed to the sebum and skin. A terminal half-life of 200-400 hours may represent the slow elimination of terbinafine from tissues such as skin and adipose. Prior to excretion, terbinafine is extensively metabolized by at least seven CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19. No metabolites have been identified that have antifungal activity similar to terbinafine. Approximately 70% of the administered dose is eliminated in the urine.In patients with renal impairment (creatinine clearance <50 mL/min) or hepatic cirrhosis, the clearance of terbinafine is decreased by approximately 50% compared to normal volunteers. No effect of gender on the blood levels of terbinafine was detected in clinical trials. No clinically relevant age-dependent changes in steady-state plasma concentrations of terbinafine have been reported.12.4 MicrobiologyTerbinafine, an allylamine antifungal, inhibits biosynthesis of ergosterol, an essential component of fungal cell membrane, via inhibition of squalene epoxidase enzyme. This results in fungal cell death primarily due to the increased membrane permeability mediated by the accumulation of high concentrations of squalene but not due to ergosterol deficiency. Depending on the concentration of the drug and the fungal species test in vitro, terbinafine hydrochloride may be fungicidal. However, the clinical significance of in vitro data is unknown.Terbinafine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections:Trichophyton mentagrophytesTrichophyton rubrumThe following in vitro data are available, but their clinical significance is unknown. In vitro, terbinafine exhibits satisfactory MIC’s against most strains of the following microorganisms; however, the safety and efficacy of terbinafine in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials:Candida albicansEpidermophyton floccosumScopulariopsis brevicaulis13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityIn a 28-month oral carcinogenicity study in rats, an increase in the incidence of liver tumors was observed in males at the highest dose tested, 69 mg/kg/day [2x the Maximum Recommended Human Dose (MRHD) based on AUC comparisons of the parent terbinafine]; however, even though dose-limiting toxicity was not achieved at the highest tested dose, higher doses were not tested.The results of a variety of in vitro (mutations in E. coli and S. typhimurium, DNA repair in rat hepatocytes, mutagenicity in Chinese hamster fibroblasts, chromosome aberration and sister chromatid exchanges in Chinese hamster lung cells), and in vivo (chromosome aberration in Chinese hamsters, micronucleus test in mice) genotoxicity tests gave no evidence of a mutagenic or clastogenic potential.Oral reproduction studies in rats at doses up to 300 mg/kg/day (approximately 12x the MRHD based on body surface area comparisons, BSA) did not reveal any specific effects on fertility or other reproductive parameters. Intravaginal application of terbinafine hydrochloride at 150 mg/day in pregnant rabbits did not increase the incidence of abortions or premature deliveries nor affect fetal parameters.13.2 Animal toxicology and/or pharmacologyA wide range of in vivo studies in mice, rats, dogs, and monkeys, and in vitro studies using rat, monkey, and human hepatocytes suggest that peroxisome proliferation in the liver is a rat-specific finding. However, other effects, including increased liver weights and APTT, occurred in dogs and monkeys at doses giving Css trough levels of the parent terbinafine 2-3x those seen in humans at the MRHD. Higher doses were not tested.14 CLINICAL STUDIESThe efficacy of Lamisil Tablets in the treatment of onychomycosis is illustrated by the response of patients with toenail and/or fingernail infections who participated in three US/Canadian placebo-controlled clinical trials.Results of the first toenail study, as assessed at week 48 (12 weeks of treatment with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 70% of patients. Fifty-nine percent (59%) of patients experienced effective treatment (mycological cure plus 0% nail involvement or >5mm of new unaffected nail growth); 38% of patients demonstrated mycological cure plus clinical cure (0% nail involvement).In a second toenail study of dermatophytic onychomycosis, in which non-dermatophytes were also cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic role of the non-dermatophytes cultured in the presence of dermatophytic onychomycosis has not been established. The clinical significance of this association is unknown.Results of the fingernail study, as assessed at week 24 (6 weeks of treatment with 18 weeks follow-up after completion of therapy), demonstrated mycological cure in 79% of patients, effective treatment in 75% of the patients, and mycological cure plus clinical cure in 59% of the patients.The mean time to overall success was approximately 10 months for the first toenail study and 4 months for the fingernail study. In the first toenail study, for patients evaluated at least six months after achieving clinical cure and at least one year after completing Lamisil therapy, the clinical relapse rate was approximately 15%.discontinued.∙ Patients should be advised to report to their physician any signs of taste disturbance, smell disturbance and/or depressive symptoms. Lamisil Tablets treatment should be discontinued.∙ Patients should be advised to immediately report to their physician or get emergency help if they experience any of the following symptoms: hives, mouth sores, blistering and peeling of skin, swelling of face, lips, tongue, or throat, difficulty swallowing or breathing. Lamisil Tablets treatment should be discontinued.∙ Patients should be advised to report to their physician any symptoms of new onset or worsening lupus erythematosus. Symptoms can include erythema, scaling, loss of pigment, and unusual photosensitivity that can result in a rash. Lamisil treatment should be discontinued.∙ Photosensitivity reactions have been reported with the use of Lamisil. Patients should be advised to minimize exposure to natural and artificial sunlight (tanning beds or UVA/B treatment) while using Lamisil.∙ Measurement of serum transaminases (ALT and AST) is advised for all patients before taking Lamisil Tablets.∙ Patients should be advised that if they forget to take Lamisil Tablets, to take their tablets as soon as they remember, unless it is less than four hours before the next dose is due. Patients should also be advised that if they take too many Lamisil Tablets they should call their physician.T2011-131Patient InformationLamisil (Lam-i-sil)(terbinafine hydrochloride)TabletsRead this Patient Information before you start taking Lamisil and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.What is Lamisil?Lamisil is a prescription antifungal medicine used to treat fungal infections of the fingernails and toenails (onychomycosis).Your doctor should do tests to check you for fungal infection of your nails before you start Lamisil.It is not known if Lamisil is safe and effective in children for the treatment of onychomycosis.Who should not take Lamisil?Do not take Lamisil if you are allergic to terbinafine hydrochloride when taken by mouth.What should I tell my doctor before taking Lamisil?Before you take Lamisil, tell your doctor if you:∙have or had liver problems∙have a weakened immune system (immunocompromised)∙have lupus (an autoimmune disease)∙have kidney problems∙have any other medical conditions∙are pregnant or plan to become pregnant. It is not known if Lamisil will harm your unborn baby. You should not start using Lamisil during pregnancy without talking with your doctor.∙are breast-feeding or plan to breast-feed. Some Lamisil passes into your milk and may harm your baby. Talk to your doctor about the best way to feed your baby if you take Lamisil.Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Lamisil may affect the way other medicines work and other medicines may affect how Lamisil works. Especially tell your doctor if you take:∙ a medicine for depression∙ a medicine for high blood pressure∙ a medicine for heart problems∙ desipramine (Norpramin)∙ caffeine∙ cyclosporine (Gengraf, Neoral, Sandimmune)∙ fluconazole (Diflucan)∙rifampin (Rifater, Rifamate, Rimactane, Rifadine)∙ cimetidine (Tagamet)If you are not sure if your medicine is one listed above, ask your doctor or pharmacist.Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.How should I take Lamisil?∙ Take Lamisil exactly as your doctor tells you to take it.∙ Lamisil comes as a tablet that you take by mouth.∙ Lamisil is usually taken:∙ 1 time each day for 6 weeks to treat fungal infections of your fingernail, or∙ 1 time each day for 12 weeks to treat fungal infections of your toenail ∙ You can take Lamisil with or without food.∙ If you forget to take Lamisil, take your tablets as soon as you remember, unless it is less than4 hours before your next dose is due. In this case, wait and take your next dose at the usualtime.∙ If you take too much Lamisil call your doctor. You may have the following symptoms: • nausea • vomiting• stomach (abdominal) pain • dizziness• rash • frequent urination• headacheWhat are the possible side effects of Lamisil?Lamisil may cause serious side effects, including:∙ liver problems that can lead to the need for liver transplant, or death. Tell your doctor right away if you get any of these symptoms of a liver problem:• nausea • upper right stomach (abdominal) pain• poor appetite • yellowing of your skin or eyes (jaundice)• tiredness • dark (tea-colored) urine• vomiting • pale or light colored stoolsYour doctor should do a blood test to check you for liver problems before you take Lamisil.∙ change in taste or loss of taste may happen with Lamisil. This usually improves within several weeks after stopping Lamisil, but may last for a long time or may become permanent.Tell your doctor if you have:• change in taste or loss of taste• poor appetite• unwanted weight loss, or• change in mood or depressive symptoms∙ change in smell or loss of smell may happen with Lamisil. This may improve after stopping Lamisil, but may last for a long time or may become permanent.∙ depressive symptoms. Tell your doctor right away if you have any of these signs or symptoms:• feel sad or worthless• change in sleep pattern• loss of energy or interest in daily activities。

DA-662A系列快速安装指南说明书

DA-662A系列快速安装指南说明书

– 1 –– 2 –– 3 –P/N: 1802006620021 *1802006620021*DA-662A Series Quick Installation GuideVersion 2.0, January 2019OverviewDA-662A computers are Arm-based, ready-to-run embedded computers designed for industrial data acquisition applications. The DA-662A computers come with 8 to 16 RS-232/422/485 serial ports, 4 Ethernet ports, and 2 USB 2.0 ports, all based on the Moxa Macro communication processor. In addition, theDA-662A-I-8/16-LX’s serial ports support 2k digital isolation and 8 kV contact, 15 kV Air ESD protection and 2 kV line-to-line, as well as 4 kV line-to-ground surge protection. The casing is a standard 1U, 19-inch wide rack-mounted rugged enclosure. The robust, rack-mountable design provides the hardened protection needed for industrial environment applications, and makes it easy for users to install the DA-662A Series on a standard 19-inch rack. The DA-662A computers are ideal for applications that require adistributed embedded technology, such as SCADA systems, plant floor automation, and power electricity monitoring applications.Package ChecklistBefore installing your DA-662A computer, verify that the package contains the following items: • 1 DA-662A Series computer • 6 jumper caps• 19-inch Rackmount Kit:2 L-shaped metal plates and 8 screws • Cross-over Ethernet cable • CBL-RJ45M9-150:150 cm, 8-pin RJ45 to DB9 (M) serial port cable • CBL-RJ45F9-150:150 cm, 8-pin RJ45 to DB9 (F) console port cable • Quick installation guide (this guide) • Document & software CD •Warranty cardNotify your sales representative if any of the above items are missing or damaged. DA-662A Series Panel LayoutFront ViewRear ViewLED IndicatorsThe following LED indicators are located on the front panel of the DA-662A Series. LED Name LED Color LED FunctionReadyGreen Power is on and functioning normally LAN1, LAN2, LAN3, LAN4Orange 10 Mbps Ethernet connection Green 100 Mbps Ethernet connection P1-P16 (Tx)GreenSerial port is transmitting dataOffSerial port is not transmitting data P1-P16 (Rx)OrangeSerial port is receiving dataOffSerial port is not receiving dataInstalling Your DA-662A ComputerDesktop MountingPlace the DA-662A on a clean, flat, well-ventilated desktop. For better ventilation, attach the 4 pads from the desktop kit to the bottom of the DA-662A, and leave some space between theDA-662A and other equipment. Do not place equipment or objects on top of the DA-662A, since doing so could damage it. Rack MountingThe DA-662A can be mounted on a standard 19-inch rack. Use the enclosed pair of L-shaped metal plates and screws to fasten the DA-662A to the rack cabinet. You can lock either the front panel or the rear panel of the DA-662A to the front side of the rack. Each L-shaped plate has 6 holes, leaving two outer or inner holes open for your convenience.Connecting Your DA-662A ComputerPower ConnectorConnect the 100-240 VAC power line to the DA-662A’s power connector. The Ready LED on the front panel will glow a steady green when the OS is ready.Ethernet PortsPin Signal 1 ETx+ 2 ETx- 3 ERx+ 6ERx-Serial PortsThe DA-662A has 8 or 16 serial ports that use RJ45 connectors. The ports can be configured independently for RS-232, RS-422, or RS-485 by software. Pin RS-232 RS-422RS-4851 DSR – –2 RTS TXD+ –3 GND GND GND4 TXD TXD- –5 RXD RXD+ Data+6 DCD RXD- Data-7 CTS – –8 DTR ––Serial Ports (DA-662A-I-8/16-LX only)Pin RS-2321 -2 RTS3 GND4 TXD5 RXD6 –7 CTS 8–Console PortsThe console port is an RJ45 RS-232 port. The pin definitions are the same as for the serial ports. Reset ButtonPress the “Reset” button on the front panel continuously for at least 5 seconds to load the factory default configuration. After the factory default configuration has been loaded, the system will reboot automatically. The Ready LED will blink for the first 5 seconds, and then maintain a steady glow once the system has rebooted. LCD ScreenThe DA-662A has an LCD screen on the front panel. The LCD screen displays 16 columns and 2 rows of text. On boot-up, the LCD screen displays the model name and firmware version, as shown here: D A - 6 6 2 A - 1 6 V ER.1.– 4 – – 5 – – 6 –/supportThe Americas: +1-714-528-6777 (toll-free: 1-888-669-2872)Europe: +49-89-3 70 03 99-0 Asia-Pacific: +886-2-8919-1230China: +86-21-5258-9955 (toll-free: 800-820-5036)India: +91-80-4172-90882019 Moxa Inc. All rights reserved.There are four push buttons on the DA-662A’s front panel. The buttons are used to enter text onto the LCD screen. The buttons are MENU, (up cursor), (down cursor), and SEL:Button ActionMENU Displays the main menuScrolls up through a list of items shown on the LCD screen’s second lineScrolls down through a list of items shown on the LCD screen’s second lineSEL Selects the option listed on the LCD screen Real-time ClockThe DA-662A’s real-time clock is powered by a lithium battery. We strongly recommend that you do not replace the lithium battery without help from a qualified Moxa support engineer. If you need to change the battery, contact the Moxa RMA service team.Powering on Your DA-662A ComputerTo power on the DA-662A, connect the power line to the DA-662A’s AC power connector (located on the right side of the rear panel), and then turn on the power switch. It takes about 30 seconds for the system to boot up. Once the system is ready, the Ready LED on the front panel will light up, and the DA-662A will display the model name and firmware version on the LCD screen.Connecting to DA-662A from a PCThere are two ways to connect to the DA-662A from a PC: throughthe serial console port or by Telnet over the network. The COM settings for the serial console port are: Baudrate = 115200 bps, Parity = None, Data bits = 8, Stop bits = 1, Flow Control = None .When using Telnet, you need to know the DA-662A’s IP address and netmask. The default LAN settings are shown below. For first-time configuration, you may find it convenient to use across-over Ethernet cable to connect directly from the PC to the DA-662A.Default IP Address NetmaskLAN 1 192.168.3.127 255.255.255.0 LAN 2 192.168.4.127 255.255.255.0 LAN 3 192.168.5.127 255.255.255.0 LAN 4192.168.6.127255.255.255.0Once the DA-662A is powered on, the Ready LED will light up, and a login page will open. Use the following default Login name and Password to proceed.Login: rootPassword: rootConfiguring the Ethernet InterfaceIf you use the console cable for first-time configuration of the Network settings, use the following commands to edit the interface file:# ifdown –a//Disable LAN1/LAN2 interface first, before youreconfigure the LAN settings. LAN 1 =eth0, LAN 2=eth1// # vi /etc/network/interfaces//check the LAN interface first//After the boot settings of the LAN interface have been modified, use the following commands to activate the LAN settings immediately: # sync ; ifup –aDeveloping Your ApplicationInstalling the DA-662A Tool ChainThe PC must have the Linux operating system pre-installed to install the DA-662A GNU Tool Chain. Redhat 7.3/8.0/9.0 Fedora Core 1/2/3/4/5 Debian 7 and later compatible versions arerecommended. The Tool Chain will use about 1 GB of your PC’s hard disk space. Use the following command to install the Tool Chain from the DA-662A Series CD: # mount /dev/cdrom /mnt/cdrom # sh /mnt/cdrom/Toolchain/arm-linux_x.x.x-Vx_Build_YYMMDDHH.shThe Tool Chain will be installed on your PC automatically.Compiling and Running Hello.cThe path to the Tool Chain is:#export PATH=“/usr/local/arm-linux-4.4.2-v4/bin:$PATH” The DA-662A software CD also includes several example programs. Here we use hello.c as an example to show you how to compile and run your applications. Type the following commands on your PC:# cd /tmp/# mkdir example# cp –r /mnt/cdrom/example/* /tmp/exampleNext, go to the hello subdirectory and type the following command: # maketo finish compiling hello.c .Finally, run the executable file that was created to generate hello-release and hello-debug .Environmental SpecificationsPower requirements100 to 240 VAC auto ranging (47 to 63 Hz for AC input)Dimensions (W×D×H): With rack-mount ears Without rack-mount ears 480 × 237 × 45 mm 440 × 237 × 45 mm Operating temperature -10 to 60°C (14 to 140°F), 5 to 95% RH Storage temperature -20 to 80°C (-4 to 176°F), 5 to 95% Regulatory approvals UL 60950-1,EN 55022/24,CISPR 22, FCC Part 15B Class A, IEC 61000-4-2 ESD:Contact 8 kV; Air 15 kV, IEC 61000-4-3 RS:3 V/m (80 MHz to 1 GHz) IEC 61000-4-4 EFT:Power 1 kV; Signal 0.5 kV, IEC 61000-4-5 Surge:Power 2 kV; Signal 4 kV, IEC 61000-4-6 CS: 3 V IEC 61000-4-8 IEC 61000-4-11Warranty 5 yearsInstall GNU cross compiler on PC LinuxPower on target and connect to PC LinuxInstall Glibc on PC LinuxInstall GDB client on PC Linux (optional)Set up cross compiler and Glibc environment variables Code program & CompileDownload to target to run and testDevelop end-user applicationProgram Debugged?NewProgramYesNo。

最刺激的游戏诸子百家之十大名将

最刺激的游戏诸子百家之十大名将

最刺激的游戏诸子百家之十大名将都说自古乱世出英雄,春秋战国,诸侯争霸,多少豪杰涌现,叱咤风云一时。

三国时期,割据混战,刘关张三人,吕布等名将也是纷纷现身,古往今来,乱世之时必出人杰,战火纷飞必多英豪。

全新战争策略类游戏《诸子百家》,将你带回战国时期那个战火纷飞,征伐四起的年代,让你身临乱世,与诸子同游,聚集战国英豪,带领麾下名将,扫荡乱世建立霸业。

当然,想要建立霸业,无猛将怎可,下面就让我来给你盘点一下《诸子百家》中的十大名将,助你慧眼识才,将名将纳入麾下。

第一将孙子:又名孙武,被后世尊为兵圣,《孙子兵法》的创始人,战国当之无愧的第一名将。

学派:兵家兵种:轻战车技能:强攻(攻击所有敌人)属性:治军:80、勇武:84、智谋:64、统率:80。

招募条件:20000威望第二将鬼谷子:纵横家之祖,却说周之阳城,有一处地面,名曰鬼谷。

以其山深树密,幽不可测似非人之所居,故云鬼谷。

内中有一隐者,自号曰鬼谷子学派:纵横家兵种:轻骑兵技能:乱战(攻击当前敌人,并随机攻击其他任意两个敌人)属性:外交:86、勇武:76、智谋:81、统率:69。

招募条件:19000威望第三将姜尚:姜尚,名望,吕氏,字子牙,或单呼牙,也称吕尚。

先后辅佐了六位周王,因是齐国始祖而称“太公望”,俗称姜太公学派:阴阳家兵种:黑衣策士技能:混乱(使敌军进入混乱,只能发动普通攻击或停止攻击)属性:炼金:83、勇武:64、智谋:73、统率:85。

招募条件:17000威望第四将孔子:儒家学派创始人,被中尊称为[至圣先师,万世师表]学派:儒家兵种:弓箭手技能:压制(攻击对方,并吸取对方的阵法能量)属性:口才:85、勇武:71、智谋:82、统率:67。

招募条件:18000威望第五将老子:道家学派创始人,主张道法自然,著有《道德经》学派:道家兵种:黑衣策士技能:混乱(使敌军进入混乱,只能发动普通攻击或停止攻击)属性:名望:82、勇武:68、智谋:80、统率:77。

有用的视频

有用的视频
英语词汇记忆法视频讲座4讲 /index.asp?id=289
许国璋英语第一册(mp3) /index.asp?id=222
许国璋英语第二册(mp3)/index.asp?id=223
《物流学导论》在线播放/index.asp?id=338
财务管理-在线播放视频讲座 /index.asp?id=336
CCTV对话《张国宝细说中国能源》 /index.asp?id=331
如何打造百年企业 /index.asp?id=196
MBA教核心大讲堂 /index.asp?id=153
服务人员的五项修炼视频(一)/index.asp?id=56
服务人员的五项修炼视频(二) /index.asp?id=57
《如何建设与管理销售队伍》 /index.asp?id=284
李践《做自己想做的人》视频下载 /index.asp?id=283
乔.吉拉德《销售员课程》在线播放 /index.asp?id=348
学英语视频 随大山万里行 /index.asp?id=207
英语FLASH学语法 /index.asp?id=186
极品英语口语 /index.asp?id=302
王强演讲-谈学英语下载 /index.asp?id=362
蓝猫英语-在线播放 /index.asp?id=182
洪恩奇境英语--在线播放 /index.asp?id=214
阶梯儿童英语全部儿歌及童谣音频/index.asp?id=130
管理-市场营销-激励-证券 余世维成功经理人(精彩) /index.asp?id=1
余世维-企业变革与文化 2005最新讲座 /index.asp?id=370

JANTXV1N759D中文资料

JANTXV1N759D中文资料
1N759A, -1 and 1N4370 thru 1N4372A, -1 DO-35 Silicon 500 mW Zener Diodes
SCOTTSDALE DIVISION
DESCRIPTION The popular 1N746 thru 1N759A and 1N4370 thru 1N4372A series of 0.5 watt Zener Voltage Regulators provides a selection from 2.4 to 12 volts in standard 5% or 10% tolerances as well as tighter tolerances identified by different suffix letters on the part number. These glass axial-leaded DO-35 Zeners are also available with an internal-metallurgical-bond option by adding a “-1” suffix. These are also available in JAN, JANTX, and JANTXV military qualifications. Microsemi also offers numerous other Zener products to meet higher and lower power applications.
WWW . Microsemi .C OM
IZT
mA 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20
IZM
* JEDEC Registered Data

D669_A[1]资料——参数及各种封装的引脚分布

D669_A[1]资料——参数及各种封装的引脚分布

UNISONIC TECHNOLOGIES CO., LTD2SD669/ANPN SILICON TRANSISTORBIPOLAR POWER GENERAL PURPOSE TRANSISTORAPPLICATIONS* Low frequency power amplifier complementary pair with UTC 2SB649/A*Pb-free plating product number: 2SD669L/2SD669ALORDERING INFORMATIONOrder Number Pin AssignmentNormal Lead Free Plating Package1 2 3 Packing 2SD669-x-AA3-R 2SD669L-x-AA3-R SOT-223 B C E Tape Reel2SD669-x-AB3-R 2SD669L-x-AB3-R SOT-89 B C E Tape Reel 2SD669-x-T60-K 2SD669L-x-T60-K TO-126 E C B Bulk 2SD669-x-T6C-K 2SD669L-x-T6C-K TO-126C E C B Bulk 2SD669-x-T92-B 2SD669L-x-T92-B TO-92 E C B Tape Box 2SD669-x-T92-K 2SD669L-x-T92-K TO-92 E C B Bulk 2SD669-x-T9N-B 2SD669L-x-T9N-B TO-92NL E C B Tape Box 2SD669-x-T9N-K 2SD669L-x-T9N-K TO-92NL E C B Bulk 2SD669-x-T9N-R 2SD669L-x-T9N-R TO-92NL E C B Tape Reel 2SD669-x-TM3-T 2SD669L-x-TM3-T TO-251 E C B Tube 2SD669-x-TN3-R 2SD669L-x-TN3-R TO-252 B C E Tape Reel 2SD669-x-TN3-T 2SD669L-x-TN3-T TO-252 B C ETubeORDERING INFORMATION(Cont.)Order Number Pin AssignmentNormalLead Free Plating Package1 2 3 Packing 2SD669A-x-AA3-R 2SD669AL-x-AA3-R SOT-223 B C E Tape Reel2SD669A-x-AB3-R 2SD669AL-x-AB3-R SOT-89 B C E Tape Reel 2SD669A-x-T60-K 2SD669AL-x-T60-K TO-126 E C B Bulk 2SD669A-x-T6C-R 2SD669AL-x-T6C-R TO-126C E C B Bulk 2SD669A-x-T92-B 2SD669AL-x-T92-B TO-92 E C B Tape Box 2SD669A-x-T92-K 2SD669AL-x-T92-K TO-92 E C B Bulk 2SD669A-x-T9N-B 2SD669AL-x-T9N-B TO-92NL E C B Tape Box 2SD669A-x-T9N-K 2SD669AL-x-T9N-K TO-92NL E C B Bulk 2SD669A-x-T9N-R 2SD669AL-x-T9N-R TO-92NL E C B Tape Reel 2SD669A-x-TM3-T 2SD669AL-x-TM3-T TO-251 E C B Tube 2SD669A-x-TN3-R 2SD669AL-x-TN3-R TO-252 B C E Tape Reel 2SD669A-x-TN3-T 2SD669AL-x-TN3-T TO-252 B C E TubeABSOLUTE MAXIMUM RATING (Ta=25℃, unless otherwise specified)PARAMETER SYMBOL RATINGS UNITCollector-Base Voltage V CBO 180 V2SD669 120Collector-Emitter Voltage 2SD669A V CEO 160VEmitter-Base Voltage V EBO 5 V Collector Current I C 1.5 A Collector Peak Current l C(PEAK) 3 A Collector Power Dissipation SOT-223 0.5 WCollector Power Dissipation TO-126 P D1 W Junction Temperature T J +150Storage Temperature T STG -40 ~ +150Note Absolute maximum ratings are those values beyond which the device could be permanently damaged.Absolute maximum ratings are stress ratings only and functional device operation is not implied.ELECTRICAL CHARACTERISTICS (Ta=25℃, unless otherwise specified)PARAMETER SYMBOL TEST CONDITIONS MIN TYP MAX UNITCollector to Base Breakdown Voltage BV CBO I C =1mA, I E =0 180 V 2SD669 120Collector to Emitter Breakdown Voltage 2SD669A BV CEO I C =10mA, R BE =∞ 160 VEmitter to Base Breakdown Voltage BV EBO I E =1mA, I C =0 5 V Collector Cut-off Current I CBO V CB =160V, I E =0 10 µAh FE1 V CE =5V, I C =150mA (Note) 60 320DC Current Gainh FE2 V CE =5V, I C =500mA (Note)30 Collector-Emitter Saturation Voltage V CE(SAT)I C =600mA, I B =50mA (Note) 1 V Base-Emitter Voltage V BE V CE =5V, I C =150mA (Note) 1.5 V Current Gain Bandwidth Product f T V CE =5V, I C =150mA (Note) 140 MHz Output Capacitance C ob V CB =10V, I E =0, f=1MHz 14 pF Note: Pulse test.CLASSIFICATION OF h FE1RANK B C DRANGE 60-120 100-200 160-320TYPICAL CHARACTERISTICS1501001502002503001310301003001,0003,000Collector C urrent, I C (mA)D C C u r r e n t T r a n s f e r R a t i o , h F EDC Current Transfer Ratio vs. Collector CurrentCollector to Emitter Saturation Voltagevs. Collector Current 1310301003001,000Collector C urrent, I C (mA)0.20.40.60.81.01.2C o l l e c t o r t o e m i t t e r s a t u r a ti o n v o l t a g e , V C E (S A T ) (V)1310301003001,00000.20.40.60.81.01.2Collector C urrent, I C (mA)Base to Emitter Saturation Voltagevs. Collector Current B a s e t o E m i t t e r S a t u r a t i o nV o l t a g e , V B E (S A T ) (V )10301003001,000Collector Current,I C (mA)04080120160200240G a i n B a n d w i d t h P r o d u c t , f T (M H z )Gain Bandwidth Product vs. Collector Current151********225102050100200Collector to Base Voltage, V CB (V)Collector Output Capacitance vs. Collector to Base VoltageC o l l e c t o r O u t p u t C a p a c i t a n c e ,C o b (p F )Area of Safe OperationCollector to Emitter Voltage, V CE (V)131010030030C o l l e c t o r C u r r e n t , I C (A )TYPICAL CHARACTERISTICS(Cont.)Base to Emitter Voltage , V BE (V)0.20.40.60.8 1.0125102050100200500Typical Transfer CharacteristicsC o l l e c t o r C u r r e n t , I C (m A )。

Moxa NPort Express DE-211快速安装指南(第七版,2011年5月)说明书

Moxa NPort Express DE-211快速安装指南(第七版,2011年5月)说明书

– 1 –– 2 – – 3 –P/N: 1802002112401NPort DE-211 Quick Installation GuideSeventh Edition, May 2011OverviewWelcome to Moxa’s NPort Express DE-211, a compact palm-sized data communication device that allows you to controlRS-232/422/485 serial devices over a TCP/IP based Ethernet network.Package ChecklistBefore installing the NPort Express DE-211, verify that the package contains the following items: • 1 NPort Express DE-211• NPort DE-211 quick installation guide • Documentation and software CD • Warranty cardOptional Accessories• NP21101: RS-232 cable: DB25 (M) to DB9 (F), 30 cm • NP21102: RS-232 cable: DB25 (M) to DB9 (M), 30 cm • NP21103: DB25 Terminal Block Kit for RS-422/485 •DK-35A: DIN-Rail Mounting Kit (35 mm)Notify your sales representative if any of the above items are missing or damaged.Hardware IntroductionThe NPort DE-211 device server has one female DB25 serial port. The four DIP switches located on the rear panel are used to select RS-232 COM mode, and one of four data modes: RS-232, RS-422, 4-wire RS-485, and 2-wire RS-485. See the “DIP Switch Settings and Explanation” section for details.Reset Button •Press the Reset button continuously for 3 sec to erase the password. After 3 sec, the Ready LED will flash on/off every half second. Release the reset button at this time to erase the password.•Press the Reset button continuously for 10 sec to load factory defaults. After 10 sec, the Ready LED will flash on/off every half second. Release the reset button at this time to load factory defaults.Hardware Installation ProcedurePlacement Options In addition to placing the DE-211 unit on a desktop or otherhorizontal surface, you may also make use of the DIN-Rail or Wall Mount options, as illustrated here.Wall MountDIN-RailDIP Switch Settings and ExplanationThe top panel of the DE-211 contains the following table, which describes how to set up the serial port using the four DIP switches located on DE-211’s rear panel.SW1 SerialConnection SW2 SW3 SW4Serial Interface Mode OFF OFF OFF RS-232 ONRS-232 ConsoleOFF ON ON RS-422ON OFF ON 4-wire RS-485 by RTS OFF Data CommON ON ON 4-wire RS-485 by ADDC ON OFF OFF 2-wire RS-485 by RTS ON ON OFF 2-wire RS-485 by ADDCSwitch SW1 controls the function of the serial port. Note that after changing the setting of SW1, the DE-211 will reboot to initialize the new setting. You must wait a few seconds for the green Ready light to blink off and then on again, indicating that the function of the serial port has been changed. Switches SW2, SW3, and SW4control the serial port’s data communication Interface Mode. (RTS stands for Ready To Send and ADDC stands for Automatic Data Direction Control.)Keep the following points in mind when setting the DIP switches: •To use the serial port as an RS-232 console connection, such as when using MOXA PComm Terminal Emulator or HyperTerminal, set SW1 to the ON position.•Some setup procedures can be carried out through a Telnet connection, in which case data is transmitted through the DE-211’s Ethernet port. However, you must set SW1 to the OFF position to establish a Telnet connection.owerPC– 4 – – 5 – – 6 –/supportThe Americas: +1-714-528-6777 (toll-free: 1-888-669-2872)Europe: +49-89-3 70 03 99-0 Asia-Pacific: +886-2-8919-1230China:+86-21-5258-9955 (toll-free: 800-820-5036)2011 Moxa Inc. All rights reserved.Software Installation InformationDetailed information about installing the software that comes with the DE-211 can be found on the NPort Documentation andSoftware CD in the “NPort Family Software Installation Guide”.Pin Assignments and Cable WiringFemale DB25 Connector PinoutsRS-232 WiringRS-422 WiringRS-485 WiringDB25 Terminal Block Kit (RS-422, RS-485-2W/4W)Environmental SpecificationsPower requirements 12 to 30 VDC150 mA (max.) at 12 V92 mA (max.) at 24 VOperating Temp. 0 to 55°C Ambient Relative Humidity 5 to 95% (non-condensing) Dimensions Including ears: 90.2 × 100.4 × 22 mm(3.55 × 3.95 × 0.87 in)Without ears: 67 × 100.4 × 22 mm (2.64 × 3.95 × 0.87 in)Surge Protection 15 KV ESD for the serial port Magnetic Isolation Protection 1.5 KV for the Ethernet port Regulatory Approvals FCC Class B, CE Class B, UL 60950-1, EN 60950-1。

力克沃斯顿 переднии

力克沃斯顿 переднии

I n s t a l l a t i o n & O p e r a t i o nR F R Z -F SES e r i a l N u m b e r :D a t e o f P u r c h a s e :I n s t a l l a t i o n a s s i s t a n c e a v a i l a b l e a t :w w w .r o c k f o r d f o s g a t e .c o m /r f t e c hR O C K F O R D F O S G A T E .C O M600 S o u t h R o c k f o r d D r i v e • T e m p e , A r i z o n a 85281 U n i t e d S t a t e s D i r e c t : (480) 967-3565 • T o l l F r e e : (800) 669-98992Dear Customer,Congratulations on your purchase of the world’s finest brand of audio products. At Rockford Fosgate we are fanatics about musical reproduc-tion at its best, and we are pleased you chose our product. Through years of engineering expertise, hand craftsmanship and critical testing procedures, we have created a wide range of products that reproduce music with all the clarity and richness you deserve.For maximum performance we recommend you have your new Rockford Fosgate product installed by an Authorized Rockford Fosgate Dealer, as we provide specialized training through Rockford Technical Training Institute (RTTI). Please read your warranty and retain your receipt and original carton for possible future use.Great product and competent installations are only a piece of the puzzle when it comes to your system. Make sure that your installer is using 100% authentic installation accessories from Rockford Fosgate in your installation. Rockford Fosgate has everything from RCA cables andspeaker wire to power wire and battery connectors. Insist on it! After all, your new system deserves nothing but the best.To add the finishing touch to your new Rockford Fosgate image order your Rockford accessories, which include everything from T-shirts to hats.Visit our web site for the latest information on all Rockford products ;or, in the U.S. call 1-800-669-9899 or FAX 1-800-398-3985. For all other countries, call +001-480-967-3565 or FAX +001-480-966-3983.Table of ContentIf, after reading your manual, you still have questions regarding this prod-uct, we recommend that you see your Rockford Fosgate dealer. If you need further assistance, you can call us direct at 1-800-669-9899. Be sure to have your serial number, model number and date of purchase available when you call.Safetyto alert the user to the presence of important instructions. Failure to heed the instructions will result in severe injury or death.This symbol with “CAUTION” is intended to alert the user to the presence of important instructions. Failure to heed the instructions can result in injury or unit damage.• To prevent injury and damage to the unit, please read and follow the instructions in this manual. We want you to enjoy this system, not get a headache.• If you feel unsure about installing this system yourself, have it installed by a qualified Rockford Fosgate technician.• Before installation, disconnect the battery negative (-) terminal to prevent damage to the unit, fire and/or possible injury.Introduction©2015 Rockford Corporation. All Rights Reserved. ROCK FORD FOSGATE and associated logos where applicable are registered trademarks of Rockford Corporation in the United States and/or other countries. All other trademarks are the property of their respective owners. Specifications subject to change without notice.Continuous exposure to sound pressure levels over 100dB may cause permanent hearing loss. High powered auto sound systems may produce sound pressure levels well over 130dB. Use common senseand practice safe sound.2Introduction 3Enclosure Assembly 4-6Installation 7Blank 8Warranty3Enclosure AssemblyFig. 1DRIVER SIDE (LEFT)PASSENGER SIDE (RIGHT)TYPICAL ASSEMBLY(Passenger Side Shown)Threaded Mounting Stud4ContentsInstallation ToolsThe following is a list of suggested tools needed for installation:Installation ConsiderationsThis section focuses on some considerations for installing your Polaris ® RZR ® Front Speaker Pod Enclosures. This manual will illustrate the installation process with a 2016 Polaris RZR XP4 Turbo.If you feel unsure about installing this system yourself, have it installed by a qualified technician.Before installation, disconnect the battery neg-ative (-) terminal to prevent damage to the unit, fire and/or possible injury.Before beginning any installation, follow these simple rules:• Be sure to carefully read and understand the instructions before attempting to install this enclosure kit.• Consult your UTV’s service manual for model specific information. Models may differ from year to year depending on factory options and aftermarket accessories added.• This dash kit is specifically designed to work with Rockford Fosgate’s Element Ready 6.5” speakers.• With the addition of an amplifier or source unit, be sure that your current charging system is in proper working order.• Visit for more comprehensive installation videos and product information.• Ratchet • 15mm Socket • 13mm Socket• 5/32” Allen Wrench• (1) Passenger Side Front Speaker Enclosure • (1) Driver Side Front Speaker Enclosure • (2) Foam Tape• (2) Threaded Studs • (4) Mounting Screws w/ Washers• (2) Mounting Bolts w/ Washers • Installation GuideInstallationApplicable Models:2014 and up RZR ® XP/XP4 10002016 and up RZR ® XP/XP4 Turbo 2015 and up RZR ®S/ XC / 4 9005InstallationThe speaker pods are designed to work with Rockford Fosgate’s RFRZ-PMXWH1 and RFRZ-K4D wire kits. After the front speaker wire is run threw both down tubes, you are ready to start the process of mounting the enclosure.NOTE: There are factory plastic bosses located on the fire wall that the new pods will be mounted to.NOTE: If you have purchased our front subwoofer enclosure (RFRZ-FWE, you must install it prior to installing this kit RFRZ-FSE).Step 1 - Bolt RemovalThere are two bolts on the kick panel that attach the plastic floor panels to the chassis of the vehicle. The bottom bolt will need to be removed.NOTE: This install shows the enclosure mounting to the passenger side of the vehicle for better visibility. The install process is the same for both sides of the vehicle.Step 2 - Attach Threaded StudOnce the bolt is removed, install the threaded stud back into the hole where the bolt was removed. This provides a new mounting point for the speaker enclosure.Step 3 - Insert Speaker WireFeed the installed speaker wire through the hole on the pod beforemounting.6Step 4 - Mount the Speaker EnclosurePosition the enclosure over the threaded stud and plastic bosses.Be sure to line up the holes before inserting mounting screws andtightening.NOTE: There are (2) mounting screws with washers, (1) mountingbolt that hold each speaker enclosure in place. Leaving the screwsand bolts loose until all hardware in place makes final fitmenteasier. Once all hardware is in place, tighten to 8 ft. lbs. of torqueto secure the pod.Overtightening will cause damage to theplastic bosses and threads in stud.Step 5 - Foam Tape PlacementFoam tape is provided to cover the speaker wire access hole afterthe wire in installed. This is to prevents moisture from gettinginside the pod and air from escaping.InstallationStep 6 - Mount Speaker Into EnclosureConnect the front speaker wires to the speaker by sliding theconnectors over the speaker terminals. Be sure to maintain properpolarity when wiring up the speaker.NOTE: The driver side speaker enclosure mounts the same way asthe passenger side. It is recommended doing one side at a time.7WarrantyRockford Corporation offers a limited warranty on Rockford Fosgate products on the following terms:Length of WarrantyPOWER Amplifiers – 2 YearsBMW® Direct Fit Speakers – 2 YearsAll other products - 1 YearAny Factory Refurbished Product – 90 days (receipt required)What is CoveredThis warranty applies only to Rockford Fosgate products sold to consumers by Authorized Rockford Fosgate Dealers in the United States of America or its possessions. Product purchased by consumers from an Authorized Rockford Fosgate Dealer in another country are covered only by that country’s Distribu-tor and not by Rockford Corporation.Who is CoveredThis warranty covers only the original purchaser of Rockford product purchased from an Authorized Rockford Fosgate Dealer in the United States. In order to receive service, the purchaser must provide Rockford with a copy of the receipt stating the customer name, dealer name, product purchased and date of purchase.Products found to be defective during the warranty period will be repaired or replaced (with a product deemed to be equivalent) at Rockford’s discretion.What is Not Covered1. Damage caused by accident, abuse, improper operations,water, theft, shipping.2. Any cost or expense related to the removal or reinstallation of product.3. Service performed by anyone other than Rockford or an Authorized Rockford Fosgate Service Center.4. Any product which has had the serial number defaced, altered, or removed.5. Subsequent damage to other components.6. Any product purchased outside the U.S.7. Any product not purchased from an Authorized Rockford Fosgate Dealer.Limit on Implied WarrantiesAny implied warranties including warranties of fitness for use and merchantability are limited in duration to the period of the express warranty set forth above. Some states do not allow limitations on the length of an implied warranty, so this limitation may not apply. No person is authorized to assume for Rockford Fosgate any other liability in connection with the sale of the product.How to Obtain ServiceContact the Authorized Rockford Fosgate Dealer you purchased this product from. If you need further assistance, call 1-800-669-9899 for Rockford Cus-tomer Service. You must obtain an RA# (Return Authorization number) to return any product to Rockford Fosgate. You are responsible for shipment of product to Rockford.EU WarrantyThis product meets the current EU warranty requirements, see your Authorized dealer for details.8。

kistler nc joining system 使用手册说明书

kistler nc joining system 使用手册说明书

NC Joining SystemsSolutions for Energy-Efficient and Highly Flexible Press-Fit andJoining ProcessesAbsolute attention fortomorrow's worldKistler develops measurement solutions consisting of sensors, electronics, systems and services. In the physical border area between emissions reduction, quality control, mobility and vehicle safety, we deliver excellence for a future- oriented world and create ideal conditions for Industry 4.0. We thereby facilitate innovation and growthfor – and with – our customers.Kistler stands for progress in motor monitoring, vehicle safety and vehicle dynamics and provides valuable data for the development of the efficient vehicles of tomorrow.Kistler measurement technology ensurestop performance in sport diagnostics,traffic data acquisition, cutting force analysisand other applications where absolutemeasurement accuracy is required.Kistler systems support all steps ofnetworked, digitalized production andensure maximum process efficiencyand profitability in the smart factories ofthe next generation.ContentsResource optimization thanks to integratedprocess monitoring 4Overview NC Joining ModulesNC Joining Module NCFT and NCFH 7NC Joining Module NCFS and NCFN 8NC Joining Module NCFE and NCFR 9System Overview 10maXYmos NC 12DIM Cable Extender 12Servo Amplifier IndraDrive 12Evaluation Objects EOs 13Kistler service: customized solutions from A–Z 14Transparent production processes ensure quality and reduce costsResource optimization thanks to integrated process monitoringThe integration of process monitoring has become a factor ofincreasing importance in industrial production. It is especially the field of press-fit and joining applications where the electromechanical NC joining systems made by Kistler tower head and shoulder above conventional systems: They play a significant role in the cutting of energy costs, the increase of system utilization and the overall boost in production efficiency.For industries dependent on automated production thepro-duction, reducing energy costs is paramount to their ability to compete in the global marketplace. It is for this reason that a widening number of companies operating in the automotive and automotive supplier industry opt for the NC joining systems made by Kistler to lower the cost of their series production. A few of the key advantages that Kistler electromechanical systems offer over pneumatic or hydraulic processes include a dramatically higher level of efficiency, press-fit forces that can be set with perfect accuracy, and an exceptionally high level of repeatability.Advantages•Enhanced quality thanks to integrated process control •Traceable process results•Higher energy efficiency, translating to savings of up to 80 %•Lower operating costs•Global presenceImproved economic efficiency thanks to optimized system utilizationOffering a comprehensive range of cutting-edge joining systems for the force range of up to 300 kN – from compact standardized single modules to custom designs tailored to the customer's specific requirements – Kistler is setting new standards on the global market.Regardless of whether they are used for transmission and engine assembly or for the assembly of wheel carrier, wheel set and chassis: The NC joining systems made by Kistler allow for high-precision control of all traversing movements performed during assembly and product inspection. Better still, the options to switch between the different measuring ranges of the NCjoining systems and to easily switch between measuring programs make it possible to use the same machine for manufacturing a wide variety of different components. The systems thereby provide for a sustained increase in system utilization andeconomical operation over the long-term.Joining control Kistler – experience it online nowWatch our animation for an up-close and personal look ofour first-rate Kistler solutions – the safest way to achieve a quality rating of 100 % in your production:/nc-joiningSize 2Type 2157B...Type 2151B...NCFH,Type 2151B...NCFS,Type 2152B...NCFN,Type 2153A...NCFE,Type 2162A...NCFR,Type 2161A...NC Joining Module NCFH, for joining processes with low forceNC Joining Module NCFT, for joining processes with low forceNC Joining Module NCFN, standard design for medium to high forceNC Joining Module NCFS, for joining processes with a narrow axle distance Type 2152B...Type 2153A...NC Joining Module NCFE, with cost optimized standard designType 2162A...NC Joining Module NCFR, for joining processes and rotational movementType 2161A...Kistler provides the optimally configured system technology for each quality assurance strategyMonitoring and control of NC Joining ModulesAdvantages•128 independent programs with up to 10 evaluation elements•Storage for 500 curves, 8 000 measuring points per curve •Flexible system concept: desktop/ wall-mounted •Measuring modules can be cascaded •Uniform operating philosophyAs the core element of the joining system, the maXYmos NC monitors and controls the entire joining process. Sporting anintuitive touch screen display and an integrated sequence control, the system offers exceptional usability and an outstanding degree of flexibility making it suitable for joining process ranging from simple to highly complex.maXYmos NC controls, monitors, evaluates and documents XY curves for joining and press-fit processes, together with NC joining modules and the IndraDrive servo amplifier that is included in the system. The shape of the measurement curves allows the quality of individual manufacturing steps, assembly groups or even an entire product to be monitored and controlled via SERCOS III in real-time. This means that optimum cycle times can be implemented with maximum repeat accuracy. Since unplanned downtimes are minimized, machine availability and the productivity of the manufacturing process are increased.Für jedes der bis zu 128 Programme besteht die Möglichkeit, einen unabhängigen Ablauf zu definieren.Monitoring, evaluation and documentationmaXYmos NC, XY Monitor for monitoring and montrolling NC Joining ModulesDIM Cable Extender, as an active cable extension between maXYmos MEM and display DIM up to 100 m operating distanceAmplifier IndraDrive C1not for NCFREvaluation objects EOsExcerpt of the evaluation elements EOs (Evaluation Objects) for maXYmos NCKistler service: customized solutions from A–ZKistler service at a glance •Consultation•Support during the commissioning of systems •Process optimization•Periodic onsite calibration of sensors •Education and training events •Development servicesKistler offers sales and service wherever automated production processes are applied.In addition to sensors and systems, Kistler offers a variety of services – from the competent consultation to the installation to the fast, worldwide supply of spare parts. An overview of our service offering can be found under . Please con-tact our local distribution partners for detailed information about our training offerings (see p. 15).From the competent consultation through the installation to the fast supply of spare parts: Kistler is present worldwide with comprehensive service and training offerings。

MXview用户手册-CH

MXview用户手册-CH

商标
MOXA 是Moxa Inc.的注册商标 本手册中的其它商标分别属于各自的产品制造公司所有。
重要声明
本手册中提供的信息可能在未事先通知的情况下有所变更,也不代表MOXA公司方面的任何承诺。 除非另有约定,本手册仅作为使用指导,本手册中的所有陈述、信息和建议不构成任何明示或暗示的担 保。MOXA保留随时对此手册及手册中所提及的产品或编程改善或修改的权利。 MOXA 公司努力使本手册提供的信息准确和适用,然而MOXA 并不对这些信息的使用承担任何责任或任 何连带责任。 产品及使用手册可能包含技术或印刷上的错误。MOXA 将定期更正这些错误,并于整合错误更新之后发 行新版文件。
技术支持联络信息
/support
Moxa 北美 Toll-free: 1-888-669-2872 Tel: Fax: Tel: Fax: +1-714-528-6777 +1-714-528-6778 +49-89-3 70 03 99-0 +49-89-3 70 03 99-99 Moxa 中国 (上海办公室) Toll-free: 800-820-5036 Tel: Fax: Tel: Fax: +86-21-5258-9955 +86-21-5258-5505 +886-2-8919-1230 +886-2-8919-1231
Moxa 欧洲
Moxa 亚太区
目录
1. 重要特性 .................................................................................................................... 1-错误!未定义书签。 基于 Web 运行 .........
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

氐评寿矫莆酵角寄丶猜宋商崩雅毯教郊瞧伊境字疵关侵蹬阜椭菜训儇筒路友诰芯闯愿税斯跋衔早晨,春梦未醒,迷恋被窝的亲近感,感受它肌肤与他的丝丝的触碰,那摄入心怀的温暖关爱,想起孩童时期,总喜欢窝在母亲的怀抱,找个自个最舒服的姿势沉沉睡去。

一声突如其来的炸响,思海里的画面变得扭曲,不经意间掉进泪雾之中,轻风卷卷,湿润的画面此时已成一根坚不可摧的束棍,抽打着着思海,噼噼啪啪,睁开双懵,眼角的湿润在一点点的清洗着耳旁的枕巾,千万的愁绪燎络心头。

今晨的雨说下就下,下的毫无征兆,身披轻薄的衣裳,走到阳台,一缕薄风带来秋雨的凉意,遥看城市街景淅淅沥沥,往日热闹的街道被秋雨稀释,只剩街边耸立的高楼,车迅驰穿城而过,要将与他无关的孤冷抛弃,似乎只有这样才能显得他的繁忙,似乎只有如此他才能将夜晚无人时的寂寞孤冷忘却。

秋雨,没有春雨的懵懂、青春洋溢,没有夏雨的热情豪迈、热辣似火,没有冬雨的冷酷无情,却又难以寻觅的冷,一股摄入心寒的共鸣,站在阳台欣赏城市的风景,寒风凌凌,吹起身上唯一的轻纱,风入心怀,不觉得冷。

是左手握着右手的随意,是一个心贴着心的温暖,是亲子回家的安详。

我喜欢秋,为之迷恋、沉醉其中。

喜欢大于渲染的天空下,轻轻地漫步于往日的河边小巷,感受雨滴带来的哀愁,贴近失意、堕落的自然,夏日繁华热闹已去,迎来的是秋日的离别凄凉,带来冬日长期沉浸在痛苦与失意之中,我喜欢秋,也许是因为秋雨的缘故,漫步在雨中,感受雨的寂寞,哀伤离愁,凭寄离恨重重,易得凋零,更多少无情风雨、秋雨丝丝,仿佛生命到了尽头,无比的绝望。

我喜欢秋,当我忧愁时,可以依靠窗台听风细雨,感叹这此第,怎的一个愁字了得,虽没有相爱之人离别时的缠绵悱恻,没有亲人逝去的悲欢离合,却别有一番滋味在心头。

这撩人心心弦的天籁之音,忽远忽近,在梦幻与现实之中交替转换。

它像极了失恋时,你的备胎在费尽心思的安慰;它像极了你生意失败时,你的家人在你的声旁默默的陪伴。

我喜欢秋,也因为他是轮船靠岸是的港湾。

是下雨时,不可或缺的雨伞。

是飞机归港是的导航。

一天,下晚自习走出教室门,贺菲走向前来,一并走着,随口问:“韩凌伟,你平常玩什么运动?”我答:“篮球、乒乓球。

”,她说:“哦,那改天一起玩吧?”我说:“可以呀。

”贺菲微笑着说:“我回宿舍了”,便拐向了女生宿舍。

贺菲是本班的女生,相貌属于英姿飒爽型的,不算甜美,但也精致。

清晨,从梦境中缓缓醒来,大脑一片空白,似乎处于一种空灵的境地,没有欲望,没有梦想,只静静的躺在床上。

说是从梦境中醒来,其实,昨晚并没有做梦,倒是前天晚上做了怪异的梦。

我之所以到了晚上才公布我的梦境,是因为白天我有另一种人生状态的使命,我想验证一下我的梦境,而这种验证需要等待一个月之后才会有结果。

我胡思乱想着,倏忽,有一束亮光透过窗棂照在我的床前,我居然有一种莫名的兴奋,那束亮光正是早晨的第一缕阳光,尽管它透过树的罅隙,透过窗棂,被折射,却依然那般的明媚,那般的温暖,那般的充满诗意,它把斑驳的树影带进我的房间,平铺在阳台的地板上,折射到我的书桌上,即平面又立体,似乎还有一种淡淡的香味在其中,形成一幅流动的画面。

我突然忘掉前日梦境的恐惧,欣欣然开怀起来,我禁不住她的诱惑,毫不犹豫的穿衣起床,我想到户外,直接感受它的温婉,和我的月季花石榴树香椿树一起。

我的这些花花树树,感谢物业早期的草坪,我义无反顾的把它改造成我的小花园。

种上月季花,石榴树,香椿树。

它们便成了我闲暇时的好朋友,我尽情的侍弄他们,无论怎样修剪,它们都顺我的意,一天天在长大。

春天的香椿叶是可以分享的,邻居们谁想吃了都可以掰,我种它们,只是为了我心中的那道风景而已。

石榴树至今没开一朵花,只是享受它夏季营造的绿荫,而月季花却是我的最爱年年繁花似锦,不仅带来蜂恋蝶舞,更是花香四溢,满足了我对它的所有愿望,而且,每年我都会增加它们的兄弟姐妹于我而言,乐此不疲,与它们而言却是群芳争艳,我们相得益彰,其乐融融,其实,生活真的很美好有阳光的日子,更是诗情画意来到我的小花园,我捧起一缕阳光,尽情的吮吸,鸟儿们也解我意,落在我旁边的树的枝丫上,叽叽喳喳,仿佛我忽略了它们,和阳光争宠来了。

到了我要亲近它们,却又忸怩,扑棱棱的飞走了。

留下我和月季和石榴树们,在阳光下尽享温情我先是修剪了石榴树根部发出的斜叉,然后又拨弄了月季花新发出的芽茎,尽管尚未蓓蕾,可那碧绿浑厚的枝叶,早已把月季花的娇媚,蜂恋蝶舞的闹景描摹的淋漓尽致了我轻轻的闭上眼睛,在阳光的沐浴下,在美妙的想象里尽享这春日以及这春日的阳光和春日的盛景不知何时起风了,阳光便被树的叶摇曳成不同的几何图形,在地面上,墙壁上,树的罅隙中形成一道道流动的风景,平日里,我最讨厌带给我过敏性鼻炎的风了,即便是春风,而此时此刻,我却那般的喜欢风了,只因为它把阳光流动起来了。

而阳光也把树的叶粉饰的碧绿,殷红,而花朵在阳光的渲染中更是姹紫嫣红,娇媚可人。

洒在大海上的阳光更是把浪花演绎的熠熠生辉而我们每天都在吃的水果蔬菜以及粮食,都包含着阳光滋润和浓郁的香味不仅如此,它还会和植物之间发生光合作用为动物们制造氧气,让我们呼吸通畅,充满活力地球因为阳光而明丽,生命因为阳光而鲜活,白昼因为阳光而充满生机,四季因为阳光而丰富多彩,充满诱惑我突然对阳光有了膜拜的感觉我突发奇想,假如这个世界没有阳光,将会是一种什么样的状态?有阳光的日子,我的心是生动的,我的生活是充满诗意的,有阳光的日子真好申城大街小巷、公园、花圃随处可见小花,她们或红色、或黄色、或蓝紫色,她们在城市一隅点缀着,绚烂着,自由自在、养眼悦目,清新了空气,美化了环境。

虽然她们有时在角落,不被人注目,她们是平凡的,精神是崇高的。

她们平凡的姿态,生活在城市,一朵朵,一簇簇,花开一生,装饰了我们的世界。

闵行秋月路有许多这样的小花,清新的蓝色花蕊,滴着水蓝,茵蕴着生命的活力,有若紫花地丁一般的可爱,喜欢紫花地丁就喜欢上她们了,俗语爱屋及鸟。

喜欢她的柔弱,喜欢她的美丽,更因为紫花地丁的神奇赋予在她身上,新颖、梦幻、怜惜。

浦东的街上有月季、栀子花,似乎淡淡的香茵蕴我的鼻息,月季是一枝平凡的花,有大红、粉红、淡紫、淡白色,她们花开绚烂,簇拥在一起,似姑娘们围在一起。

如果家阳台上种上月季,可以妩媚暮春和夏季,只要给她充足的养份。

大红的月季喜庆、热烈,红红火火。

整个阳台花红覆盖,浓郁、喜气,沦漪荡漾一种精神活力,整个季节红了,生活红了,阳台红了,怎不欣喜、快乐?我上海的姐姐家养了许多月季,栅栏围着月季,她们喜庆的笑脸伸出了围栏,一簇簇月季微风吹拂,笑意空气中迷散,月季浅施淡妆,高雅、端庄。

月季的笑,仿佛我受了感染,想轻拥一簇妩媚的笑容,可终究不敢。

松江复美药房边上有个卖车的安徽师傅,他经营电动车,兼修理自行车、电瓶车、摩托车等。

附近的小区人、快递员、过路的修车人,他给于他们无微不至的服务,他在这生活了廿载时光,生意不是很多,这里人稀少,空间宽广,我问他,为何不去人多点的地方?他说,我卖车兼做后勤保障,修车只是形式,相当于有一个就挣一个。

他手艺很好,人一脸的诚实,我喜欢他这样诚实、可靠的师傅。

小区人电动车小毛病他帮捣捣,只要不加零件,他一般不收费,有人要付钱,他说算了,下次一道付吧他生活在城市,服务于城市人民,他多似一朵平实、朴素的花,让人喜爱、敬慕他一生的时光在城市绽放光彩。

闵行浦秀路有一群环卫女工,她们和男人环卫工一样,一年四季工作在环卫战线,年年如一日,她们每天清晨就开始工作,如一朵家乡朴实的芦苇。

有一天我把垃圾倒给她们,她们莞尔一笑,笑得灿烂如花,她们笑得如阳光一般的和煦,她们的美丽定格在心间,多么美的环卫女工。

浦行路有一家卖水果的女子,一年四季忙碌水果生意,小小的生意很辛苦的,不仅仅愁卖,而且愁买,鲜果有保鲜期,比如香蕉、西瓜。

时间长了香蕉熟透了,西瓜遇下雨,要坏得。

她常年忙碌生意,血压低、头晕、脸色无华,我知道她可能气血不足、肾阳虚弱,卖给她一盒复方阿胶浆。

她来了二次,买了好几样补品,我还没有照顾她水果生意,巧合我突然离开了浦行路,我心里总觉得亏欠她一个礼节。

我不知道她生意好坏,我想做生意是做人的道理,人做好,生意销路就打开了。

她人漂亮、朴实、勤劳,用自已的一双手吃饭,上天一定会眷顾她的,必会给她真诚、善纳。

我想人不管何时、何地都需努力、奋斗,努力了、尽力了,生意好坏无怨无悔,生活有付出,必将有回报,任何时候不以善小而不为,不以恶小而为之。

申城,我来来去去好多年,一直在风景的路上,平凡的花儿见了很多,平凡、朴实的人也遇到很多,她们都是任劳任怨战斗在基层的人员,她们努力拼搏,她们坚持不懈,人生的路上她们默默奉献青春和年华,她们如一朵朴实的花,如花绽放一生,她们永恒值得我们学习。

此文献给那些默默无闻、辛勤的工作者管原意为细长而中空之物,其四周被堵塞,中央可通达。

使之闭塞为堵;使之通行为疏。

管,就表示有堵有疏、疏堵结合。

所以,管既包含疏通、引导、促进、肯定、打开之意;又包含限制、规避、约束、否定、闭合之意。

[2]理,本义为顺玉之纹而剖析;代表事物的道理、发展的规律,包含合理、顺理的意思[2]。

管理犹如治水,疏堵结合、顺应规律而已。

所以,管理就是合理地疏与堵的思维与行为去过云南的丽江,那里的石板街让我震撼满街都是麻石铺就,麻石大小均匀、边角整齐,呈长方型,约40*60见方,横铺竖砌,隙缝交错,平坦如泊油马路。

假如把它竖起来观看,就像一面青砖砌起来的山墙。

石板街的北端是一条水渠,雪山的溶水从这里流入古老的街巷。

街的入口一架水车啧啧啊啊,在水流的推动下吟唱那西族无词的歌谣,沿街排开的还有木板围拢的民居。

我像是走进了自己的故乡,但却不是真实的故乡,像是梦幻中的故乡。

因为我的故乡也有一条古老的石板街,有沿街排开的骑楼,有雨霁之后架在山梁上的彩虹。

但它的石板街没有丽江这样的整齐唯美,这样的气势浩荡,这样的浑雄豪迈。

它没有游人的足迹,没有游人的跫音,没有厚重的文化和历史遗存。

它只是默默地悄无声息的静卧在桂西北的崇山峻岭之中。

只有像我这样的异乡游子提起它、想念它、回忆它的时候,它才拭去那层迷蒙的山雾,绽露一下它的面容。

记得是我先问的父亲老家的石板街是什么年代铺的?父亲说不清楚。

那时候的父亲忙于事业,忙于家小。

等到父亲步入暮年,岁月沉淀了他苍老的记忆,这个时候,父亲反过来问我老家的石板街是什么年代铺的?我的回答和先前父亲的回答一样不清楚。

对于故乡的石板街,论起它的整齐,论起它的气势,论起它的美学特质,相比于丽江的石板街的确差的很远。

但是细细琢磨之后也有它的非同一般。

单就石板而论,丽江的石板是整条凿刻好的麻石,尺寸规整,标准的长方形,铺就起来省时、省事、美观。

而故乡的石板则是形状不一,有大有小,是乱铺,费事费力。

可是这一乱却乱出来水平。

相关文档
最新文档